US20030023023A1 - Hydrolytically degradable polymers and hydrogels made therefrom - Google Patents

Hydrolytically degradable polymers and hydrogels made therefrom Download PDF

Info

Publication number
US20030023023A1
US20030023023A1 US10/076,018 US7601802A US2003023023A1 US 20030023023 A1 US20030023023 A1 US 20030023023A1 US 7601802 A US7601802 A US 7601802A US 2003023023 A1 US2003023023 A1 US 2003023023A1
Authority
US
United States
Prior art keywords
polymer
hydrolytically degradable
integer
oligomer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/076,018
Inventor
J. Harris
Michael Bentley
Xuan Zhao
Xiaoming Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/076,018 priority Critical patent/US20030023023A1/en
Application filed by Shearwater Corp filed Critical Shearwater Corp
Publication of US20030023023A1 publication Critical patent/US20030023023A1/en
Assigned to NEKTAR THERAPEUTICS AL, CORPORATION reassignment NEKTAR THERAPEUTICS AL, CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SHEARWATER CORPORATION
Priority to US10/412,642 priority patent/US7074878B1/en
Priority to US11/377,973 priority patent/US7259224B2/en
Priority to US11/890,162 priority patent/US7608678B2/en
Assigned to NEKTAR THERAPEUTICS reassignment NEKTAR THERAPEUTICS MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NEKTAR THERAPEUTICS AL, CORPORATION
Priority to US12/559,162 priority patent/US7772357B2/en
Priority to US12/826,664 priority patent/US7910685B2/en
Priority to US13/027,218 priority patent/US8119756B2/en
Priority to US13/344,434 priority patent/US8283434B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/02Aliphatic polycarbonates
    • C08G64/0208Aliphatic polycarbonates saturated
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20General preparatory processes
    • C08G64/38General preparatory processes using other monomers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/18Block or graft polymers
    • C08G64/183Block or graft polymers containing polyether sequences

Definitions

  • This invention generally relates to water soluble, hydrolytically degradable, and nonpeptidic polymers, and particularly to polymers and gels therefrom that are suitable for medical devices, drug enhancement and in vivo delivery of biologically active agents.
  • Conjugation of agents having a known or potential therapeutic benefit to water soluble, non-immunogenic polymers can impart to the agent desirable characteristics including, among others, improved solubility, greater stability, and reduced immunogenicity. It has become increasingly important in the pharmaceutical industry to develop conjugates having these characteristics so as to increase the number of options for therapeutic benefit.
  • PEG poly(ethylene glycol)
  • Therapeutic agents conjugated to PEG are sometimes said to be “PEGylated.”
  • PEGylated therapeutics have been developed that exhibit enhanced water solubility, longer circulation lifetimes, and lower immunogenicity as compared to the unconjugated therapeutic agent. Because of the rapid motion and heavy hydration of the polymer, PEGs usually are of much higher apparent molecular weight than the therapeutics to which they are attached. Thus, they tend to mask the therapeutic agent from the immune system and to preclude excretion through kidneys.
  • PEG is commonly used to describe any of a series of polymers having the general formula HO—(CH 2 CH 2 —O) n —H, where “n” represents the number of ethylene oxide monomers in the polymer.
  • the parent polymer is generally unsuitable for attachment to a therapeutic agent.
  • Hydroxyl groups are relatively unreactive toward groups commonly present on therapeutic agents and thus PEG normally has to be “activated” by converting at least one end hydroxyl group into a more reactive form. It is also usually important to activate the PEG polymer with a terminal group that is selective in its reactions. For example, several PEG derivatives have been developed that are more likely to react with amine groups. Others have been developed that preferentially react with thiol groups.
  • PEG derivatives may have to meet a number of requirements, depending on the specific application.
  • the PEG derivative should usually have a desirable and suitably selective reactivity at physiologic conditions of temperature, pressure, and pH to preserve the activity of the unconjugated protein.
  • PEG derivatives have been used in combination with other polymers to prepare insoluble gels in which drugs can be entrapped or chemically bound.
  • Sawhney et al., Macromolecules, 26:581 (1993) describes the preparation of block copolymers of PEG with polyglycolide or polylactide blocks at both ends of the PEG chain. The copolymers are then activated by terminal substitution with acrylate groups, as shown below.
  • the glycolide blocks are the —O—CH 2 —CO— units.
  • the addition of a methyl group to the methylene gives a lactide block; n can be multiples of 2.
  • Vinyl polymerization of the acrylate groups produces an insoluble, crosslinked gel with a polyethylene backbone.
  • polylactide or polyglycolide segments of the polymer backbone shown above which are ester groups, are susceptible to slow hydrolytic breakdown, with the result that the crosslinked gel undergoes slow degradation and dissolution.
  • the hydrogel degrades in vivo and can result in non-PEG components being released into the blood stream, which can be undesirable.
  • This invention provides a water soluble, nonpeptidic polymer having two or more oligomers linked together by hydrolytically degradable carbonate linkages.
  • the polymer can be hydrolytically degraded into small oligomers in an aqueous environment, including in vivo conditions.
  • the polymer is easy to prepare and the molecular weight of the oligomers resulting from polymer degradation can be easily controlled, which can be desirable for some applications.
  • the polymer can be conjugated to a biologically active agent such as a protein or peptide.
  • the polymer can impart desirable characteristics to the conjugates of improved water solubility and reduced immunogenicity.
  • the polymer is useful for preparing insoluble cross linked structures, including hydrogels, that are hydrolytically degradable into soluble polymers of predetermined molecular weight.
  • the oligomers are alkylene oxide oligomers.
  • the oligomers are ethylene oxide oligomers, and the polymer is a poly(ether carbonate) having the formula of:
  • n is from about 1 to 2,000, normally from 2 to 2,000, and m is from about 2 to 200. Since carbonate linkages are hydrolytically degradable under mild conditions, the polymer will hydrolyze to produce oligomer fragments of much lower molecular weight than the starting polymer:
  • this new polymer can degrade in the body and thus facilitates removal of the polymer from the body.
  • the degradation products are themselves normally nontoxic small PEGs that typically are rapidly cleared from the body.
  • the polymer can be prepared in a number of ways.
  • the poly(ether carbonate) is prepared by polymerizing an activated oligomer having the formula of:
  • n can be from about 2 to 2000 and Z is a reactive leaving group such as N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl.
  • the polymer can be prepared by polymerizing ethylene oxide oligomers of the formula:
  • n can be from about 2 to 2000 with an activating molecule of Z-O—CO 2 -Z, where Z is as described.
  • [0019] can be polymerized with a bifunctional ethylene oxide oligomer:
  • n and Z are as described above, to form the poly(ether carbonate).
  • the polymerization reactions may be conducted either in an organic solvent or in a melt, in the presence of an organic base.
  • suitable solvents include acetonitrile, THF, dimethylformamide, dimethylsulfoxide, benzene, toluene, the xylenes, chloroform, and methylene chloride.
  • suitable organic bases include triethylamine, pyridine, quinoline, 4,4-dimethylaminopyridine and triethylamine.
  • the polymerization reactions can be conducted at a temperature of from about 37° C. to 100° C., typically from about 45° C. to 100° C., and advantageously from about 70° C. to 90° C.
  • the polymer of this invention can be modified at one termius with alkyl or aryl groups to make one end of the polymer inert.
  • the polymer can be activated at one or more of its termini to form a terminal reactive moiety.
  • a modified or activated poly(ether carbonate) of this invention can be represented as:
  • X and Y can independently be H, alkyl, alkenyl, aryl, and reactive terminal moieties, including N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, or others.
  • X and Y can include linker groups terminating in active groups such as aldehyde N-maleimidyl or —S—S-ortho-pyridyl. A wide variety of activating groups and linkers can be used.
  • the activated polymer of this invention can be reacted with an active group on a biologically active agent, such as a protein or peptide, to form a conjugate.
  • a biologically active agent such as a protein or peptide
  • N-succinimidyloxy, 1-benzotriazolyloxy, and p-nitrophenyloxy are leaving groups suitable for the formation of a carbamate linkage between the polymer and a biologically active agent having an amino group.
  • proteins, peptides, amino drugs, or amino carbohydrates can be linked to such activated polymers.
  • X is H
  • Y N-succinimidyloxycarbonyl
  • a conjugate can be formed of the following formula:
  • the polymer of this invention can be activated to contain a terminal reactive moiety that is reactive with thiol, including, for example, iodoacetamide, vinylsulfone, maleimide, or S—S-ortho-pyridyl, which moiety is then reacted with the thiol group to form a thiol site-specific conjugate of the protein.
  • thiol including, for example, iodoacetamide, vinylsulfone, maleimide, or S—S-ortho-pyridyl
  • the polymer of this invention When the polymer of this invention is activated at two termini, it can be used as a crosslinking agent to crosslink a multifunctional molecule to form a hydrolytically degradable hydrogel.
  • multifunctional molecules suitable as “backbones” in formation of hydrogels include proteins such as collagen, aminocarbohydrates such as chitosan, polyamines such as polylysine and poly(vinylamine), and multi-armed or branched poly(ethylene glycol) amines.
  • the hydrogels of this invention are useful in many biomedical applications such as drug delivery, surgical adhesion prevention, wound and scar healing, bioadhesives and surgical implants.
  • the polymer of this invention can be activated by attachment of terminal vinyl groups.
  • This activated polymer can be self-polymerized in the presence of a conventional vinyl polymerization catalyst to form a hydrolytically degradable hydrogel.
  • this invention provides a versatile polymer that is especially suited for conjugating to a biologically active agent and for forming a hydrogel.
  • the polymer is easy to prepare and can be synthesized in large quantities.
  • the polymer can be formed in a single reaction with multiple degradable carbonate linkages in the backbone.
  • the conjugate and hydrogel of this invention can be degraded under physiological conditions. The degradation generates oligomers of predetermined molecular weight that can be easily cleared from the body.
  • polymer means a molecule, formed by the chemical union of two or more oligomer units.
  • the chemical units are normally linked together by covalent linkages.
  • the two or more combining units in a polymer can be all the same, in which case the polymer is referred to as a homopolymer. They can be also be different and, thus, the polymer will be a combination of the different units. These polymers are referred to as copolymers.
  • oligomer is used herein to mean a molecule, typically an organic molecule, which in itself is formed by the chemical union of two or more monomer units.
  • the monomer units of an oligomer may be different or all the same.
  • An oligomer is capable of reacting with another oligomer which is same or different, in a polymerization reaction to form a polymer.
  • the term oligomer by no means limits the size of the molecule or the number of combining units or monomers in the oligomer. Rather, “oligomer” is used to indicate a unit for forming a polymer of the invention.
  • the structure of an oligomer in a polymer may be somewhat different in chemical structure from the oligomer prior to polymerization because of the polymerization reaction and the formation of covalent linkages.
  • group and “moiety,” are all used herein interchangeably to refer to a distinct, definable portion or unit of a molecule.
  • structure of a group or moiety may include another smaller group or moiety.
  • a functional group of —O—CO 2 -Z includes Z which may be a reactive group or moiety including N-succinimidyl or 1-benzotriazolyl.
  • biologically active agent when used herein means any substance that can impact any physical or biochemical properties of a biological organism including, but not limited to, viruses, bacteria, fungi, plants, animals and humans.
  • a biologically active agent can be any substance intended for the diagnosis, cure, mitigation, treatment, or prevention of a disease in humans or other animals, or to otherwise enhance the physical or mental well being of humans or animals.
  • biologically active agents include, but are not limited to, organic and inorganic compounds, proteins, peptides, lipids, polysaccharides, nucleotides, DNAs, RNAs, other polymers, and derivatives thereof.
  • biologically active agents examples include antibiotics, fungicides, anti-viral agents, anti-inflammatory agents, anti-tumor agents, cardiovascular agents, anti-anxiety agents, hormones, growth factors, steroidal agents, and the like.
  • Biologically active agents include microorganisms such as bacteria and yeast cells, viral particles, plant or animal or human cells or tissues, and the like, in their native or modified forms.
  • the oligomers used in the practice of the invention should be selected so that they and the degradation products of the polymer of this invention are water soluble and can easily be excreted from animal bodies under natural physiological conditions. They should be non-toxic, or at least of acceptable low toxicity, and should not cause a substantial adverse effect in human or animal bodies.
  • alkylene oxide oligomers are useful in forming the polymer of this invention.
  • an alkylene oxide “homo-oligomer” is used having the formula of HO—(—CHRCH 2 —O) n —H, where R is H or an alkyl, including methyl.
  • Suitable oligomers also include alkylene oxide “co-oligomers,” which are composed of different alkylene oxide monomers in which R is varied independently along the chain.
  • An example of a co-oligomer is a structure in which two different R groups are present in a block such as HO—(—CHR 1 CH 2 —O—) n —(—CHR 2 CH 2 —O—) m —H, where n and m can be varied independently.
  • An example of this type of block structure is the case in which R 1 is hydrogen and R 2 is methyl.
  • Block oligomers can exhibit surface activity.
  • Degradable surfactants are useful in drug delivery systems and can be used to form micelles and thermally reversible gels.
  • Random oligomers in which R 1 and R 2 are randomly placed along the oligomer chain are also useful.
  • the oligomers can be branched, as in the formula
  • R 3 is a core branching moiety, including glycerol or pentaerythritol
  • R 1 is alkyl
  • n can range from 2 to hundreds
  • m is at least 3.
  • a suitable oligomer can be formed from about 2 to 2000 monomers. However, the size of the oligomers used can vary so long as the above requirements are met. Normally an oligomer has from about 5 to 500 monomers. Advantageously, an oligomer has from about 10 to 50 monomers.
  • An oligomer can be prepared by polymerizing or co-polymerizing monomers, and the size or molecular weight of the oligomer can be controlled by limiting the extent of this polymerization reaction.
  • the oligomers contained in the polymer of this invention can be the same or different types of oligomers, or oligomers of the same type but different sizes. Therefore, the polymer of this invention can be either a homopolymer or heteropolymer.
  • the polymer of this invention typically has one single linear polymer backbone with two termini.
  • branched polymers and star polymers are also contemplated that have two or more linear polymers, at least one of which is the linear polymer backbone of this invention, covalently linked to a central branching core.
  • the polymer of this invention can have an inert terminal moiety, typically H, alkyl, and aryl.
  • the alkyl and aryl groups can be substituted or unsubstituted, and normally are methyl, ethyl, phenyl, etc.
  • the polymer can also have one or more reactive moieties capable of reacting with a moiety in another molecule, such as an amino group or a thiol group on a protein.
  • reactive moieties include, but are not limited to, acryloyl, alkenyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, o-pyridyldithiyl, and the like.
  • the hydrolytically degradable polymer is a poly(ether carbonate) composed of two or more alkylene oxide oligomers and/or alkylene oxide monomers covalently linked together by carbonate linkages.
  • the poly(ether carbonate) can have the formula of
  • R 1, R 2, R 3, R 4, and R 5 are alkyl groups which may be linear, branched, substituted or unsubstituted, and they can be same or different; typically R 1, R 2, R 3, R 4, and R 5 are ethyl;
  • a, b, c, d, e each is an integer of from 1 to about 2000, normally from about 5 to 500, and advantageously from about 10 to 50;
  • h, i, j, and k each is an integer of from 0 to about 100, and the sum of h, i, j, and k is from about 2 to 200, normally from about 5 to 100, and advantageously from about 10 to 50; and
  • each of X and Y is hydrogen, alkyl, alkenyl, aryl, or reactive moieties as described above, and X and Y can be same or different.
  • the poly(ether carbonate) of this invention has the formula of:
  • n is an integer of from about 2 to 2000, normally from about 5 to 500, and advantageously from about 10 to 50; m is an integer of from about 2 to 100, typically from about 5 to 100, and advantageously from about 10 to 50, and wherein X and Y can be same or different and each independently is H, alkyl, alkenyl, aryl, or a reactive moiety, acryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.
  • poly(ether carbonate) contains repeating ethylene oxide oligomers linked by carbonate linkages that can be hydrolytically cleaved. Such hydrolytic cleavage leads to ethylene oxide oligomers and carbon dioxide. Therefore, the poly(ether carbonate) differs substantially from poly(ethylene glycol) or PEG in having multiple degradable backbone carbonate linkages that allow the polymer to be broken down into many smaller oligomers. Since the rate of degradation of the polymer is proportional to the number of degradable carbonate linkages present, and since the size and number of the oligomers can be predetermined, substantial control over both degradation rate and the size of the degradation products is thus possible.
  • one or more oligomers as described above are provided each having a hydroxyl group at one terminus and a functional group of —O—CO 2 -Z at another terminus.
  • the oligomers are then polymerized or co-polymerized in a condensation polymerization reaction under conditions sufficient to form a hydrolytically degradable polymer.
  • the functional group —O—CO 2 -Z is capable of reacting with a hydroxyl group to form a carbonate linkage.
  • Z can be any reactive leaving groups so long as the functional group can react with a hydroxyl group to form a carbonate linkage. Examples of suitable leaving groups include N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl.
  • Methods for preparing an oligomer having a functional group —O—CO 2 -Z as described above are well known in the art, and are disclosed in U.S. Pat. Nos. 5,650,234, 5,281,698 and 5,468,478; Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem. Biotech., 27:45 (1991), all of which are incorporated herein by reference.
  • oligomers can be polymerized together.
  • monomers having a hydroxyl terminus and a functional group —O—CO 2 -Z at another terminus can also be included in the polymerization mixture.
  • an ethylene oxide oligomer having a formula of HO—(—CH 2 CH 2 —O—) n —O—CO 2 -Z, where Z is a reactive leaving group such as N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl.
  • Z is a reactive leaving group such as N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl.
  • This oligomer is then polymerized under controlled conditions to provide the above poly(ether carbonate).
  • a first oligomer which is a bifunctional oligomer having a first functional group of —O—CO 2 —W at one terminus and, at another terminus, a second functional group of —O—CO 2 -Z. Both functional groups are capable of reacting with a hydroxyl group to form a carbonate linkage.
  • Z and W are reactive leaving groups, and can be any leaving groups known in the art so long as the functional groups containing them, as stated above, are capable of reacting with a hydroxyl group to form a carbonate linkage.
  • Z and W can be same or different.
  • the preferred Z and W are N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl. Two or more different bifunctional oligomers can also be used in the same polymerization reaction.
  • bifunctional oligomers are similar to those for making the monofunctional oligomers described above.
  • Z and W are the same, and the bifunctional molecule Z-oligomer-Z can be provided by activating an oligomer having two hydroxyl terminal groups, with an activating molecule having the formula of Z-O—CO 2 -Z.
  • Suitable examples of the activating molecule include, disuccinimidylcarbonate, bis(1-benzotriazolyl) carbonate and bis(p-nitrophenyl) carbonate. See, e.g., U.S. Pat. Nos. 5,281,698; 5,650,234; Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem. Biotech., 27:45 (1991), all of which are incorporated herein by reference.
  • a second oligomer is also provided having two terminal hydroxyl groups. This second oligomer is then polymerized with the first oligomer to form the polymer of this invention.
  • Two or more types of bifunctional oligomers can be used in the same polymerization reaction.
  • two or more types of oligomers having two terminal hydroxyl groups can also be used in a polymerization reaction.
  • the polymer formed therefrom will be a homopolymer having a single type of repeating unit or oligomer linked with hydrolytically degradable linkages. Otherwise, a heteropolymer or block polymer or terpolymer will be made containing different types of oligomers in the polymer backbone.
  • [0064] can be prepared by co-polymerizing a first ethylene oxide oligomer having a formula of
  • Z is preferably N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl.
  • [0066] can be prepared by reacting Z-O—CO 2 -Z with HO—(—CH 2 CH 2 —O—) n —OH, under the conditions disclosed in U.S. Pat. No. 5,281,698.
  • one or more oligomers having two hydroxyl terminal groups are polymerized directly with an activating molecule having the formula of Z-O—CO 2 -Z to form the hydrolytically degradable polymer.
  • an activating molecule having the formula of Z-O—CO 2 -Z to form the hydrolytically degradable polymer.
  • [0068] can also be prepared by co-polymerizing an activating molecule Z-O—CO 2 -Z and the oligomer HO—(—CH 2 CH 2 —O—) n —OH, under conditions sufficient to form the poly(ether carbonate).
  • either one oligomer is used to generate a homopolymer, or two or more different oligomers can be used in the same polymerization reaction to produce a heteropolymer, or block polymer or terpolymer.
  • the polymerization reactions are conducted under conditions sufficient to form the hydrolytically degradable polymer of this invention.
  • the polymerization reaction in each of the above-described methods is a condensation reaction. Many different known reaction conditions can be used.
  • a catalyst is included in the polymerization reaction mixture. Examples of suitable catalysts are organic bases, including triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine. Amine bases such as 4,4-dimethylaminopyridine and triethylamine are preferred.
  • the polymerization can be conducted in either melt or solvent.
  • suitable solvents include, but are not limited to, acetonitrile, THF, dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes, chloroform, and methylene chloride.
  • the polymerization reaction rate and the extent of polymerization, which determines the average molecule weight of the final hydrolytically degradable polymer product can be partly controlled by the reaction temperature and the reaction time.
  • Suitable reaction temperature can vary from about 0° C. to 100° C. Higher reaction temperatures lead to greater reaction speed.
  • the polymerization reaction is conducted at a temperature of from about 37° C. to 100° C., typically from about 45° C. to 100° C. and advantageously from about 70° C. to 90° C.
  • the temperature needs be maintained at a certain minimum temperature in order to keep the reaction mixture at a melt state.
  • the polymerization reactions would be predicted to lead to polymers with an activated carbonate terminal group.
  • NMR analysis of the polymer products indicates that the terminal groups of the hydrolytically degradable polymer prepared therefrom often are hydroxyl groups. While not wishing to be bound by any theory, it is believed that this is caused by reaction with a small amount of water present as an impurity in the reaction. Any small amount of remaining terminally activated carbonate may be removed by hydrolyis in water for a short period or near a neutral pH. The terminal activating groups are much more sensitive to water than are the degradable carbonate linkages.
  • the polymer of this invention can optionally be activated at one or all termini, thus providing an activated polymer capable of being covalently linked to another molecule, including, for example, a protein, to form a conjugate.
  • the polymer can also be capped at one terminus by an inert group and at another terminus by a reactive moiety.
  • the polymer of this invention can be activated at its terminus to form a terminal reactive moiety by methods well known to those familiar with the art of organic or polymer chemistry.
  • the well established methods in the broad field of poly(ethylene glycol) chemistry are generally useful, and such methods should be apparent to a skilled artisan.
  • the polymer can be activated at one terminus, or all termini, in which case, the reactive moieties at different termini can be same or different.
  • the polymer may be activated to form a terminal moiety of N-succinimidyl carbonate (see e.g., U.S. Pat. Nos. 5,281,698, 5,468,478), amine (see, e.g., Buckmann et al. Makromol. Chem. 182:1379 (1981), Zaplipsky et al. Eur. Polym. J. 19:1177 (1983)), hydrazide (See, e.g., Andresz et al. Makromol. Chem. 179:301 (1978)), succinimidyl propionate and succinimidyl butanoate (see, e.g., Olson et al.
  • succinimidyl succinate See, e.g., Abuchowski et al. Cancer Biochem. Biophys. 7:175 (1984) and Joppich et al. Macrolol. Chem. 180:1381 (1979), succinimidyl ester (see, e.g., U.S. Pat. No. 4,670,417), benzotriazole carbonate (see, e.g., U.S. Pat. No.
  • glycidyl ether see, e.g., Pitha et al. Eur. J. Biochem. 94:11 (1979), Elling et al., Biotech. Appl. Biochem. 13:354 (1991), oxycarbonylimidazole (see, e.g., Beauchamp, et al., Anal. Biochem. 131:25 (1983), Tondelli et al. J. Controlled Release 1:251 (1985)), p-nitrophenyl carbonate (see, e.g., Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem.
  • polymer of this invention can also be linked to the amino acid lysine to form a di-substituted lysine, which can then be further activated with N-hydroxysuccinimide to form an active of N-succinimidyl moiety (see, e.g., U.S. Pat. No. 5,932,462). All of the above references are incorporated herein by reference.
  • the polymer of this invention may be activated to form a terminal reactive moiety of N-succinimidyl carbonate or 1-benzotriazolyl carbonate by reacting the polymer with di-N-succinimidyl carbonate or di-1-benzotriazolyl carbonate respectively.
  • terminal reactive moieties such as N-maleimidyl and o-pyridyldithiyl may be prepared by reacting the polymer with activated carbonates connected to N-maleimidyl or o-pyridyldithiyl by linker groups. Terminal aldehyde and acetal moieties can be attached by linking groups. Terminal acid groups can be attached by reaction of the above active carbonates with amino acids or other acid linkers. These acids can then be activated by formation of active esters such as succinimidyl active esters.
  • the polymer of this invention activated or not, as prepared by the above methods, can be easily purified from the reaction mixture.
  • Many methods known in the art can be used.
  • a preferred method for purifying the polymer and its derivatives is by precipitation from a solvent in which they are essentially insoluble while the reactants are soluble. Suitable solvents include ethyl ether or isopropanol.
  • ion exchange, size exclusion, silica gel, and reverse phase chromatography can also be useful.
  • the activated polymer is used to form a conjugate with a biologically active agent.
  • the conjugate comprises the polymer of this invention covalently linked to a biologically active agent. Because the polymer of this invention is hydrolytically degradable in vivo and can be cleaved at the carbonate linkages, thus forming smaller oligomers, the conjugate is especially useful for controlled delivery of the bound agent into animal bodies. Since the polymer in the conjugate is susceptible to breakdown into smaller oligomers, the polymer typically is excreted from animal bodies faster than a polymer of similar size that is not degradable. Thus, potential adverse effects that may be caused by a large polymer's long period of stay in the body is avoided. Therefore, conjugation of the polymer of this invention to a biologically active agent can provide for a sufficient circulation period for the agent while minimizing any adverse effects of the polymer.
  • the linkage between the biologically active agent and the polymer of this invention can be stable or hydrolytically degradable.
  • substantially all of the polymer can be cleaved off the biologically active agent under physiological conditions, releasing the agent substantially in its native form inside the body.
  • Methods for forming a hydrolytically degradable linkage between a biologically active agent and a water soluble polymer are well known in the art and should be apparent to a skilled artisan.
  • ester linkages formed by the reaction of PEG carboxylic acids or activated PEG carboxylic acids with alcohol groups on a biologically active agent generally hydrolyze under physiological conditions to release the agent.
  • hydrolytically degradable linkages include carbonate linkages; imine linkages resulted from reaction of an amine and an aldehyde (see, e.g., Ouchi et al., Polymer Preprints, 38(1):582-3 (1997), which is incorporated herein by reference.); phosphate ester linkages formed by reacting an alcohol with a phosphate group; hydrozone linkages which are reaction product of a hydrazide and an aldehyde; acetal linkages that are the reaction product of an aldehyde and an alcohol; orthoester linkages that are the reaction product of a formate and an alcohol; peptide linkages formed by an amine group, e.g., at an end of a polymer such as PEG, and a carboxyl group of a peptide; and oligonucleotide linkages formed by a phosphoramidite group, e.g., at the end of a polymer, and a 5′ hydroxyl group an
  • the polymer of this invention must be activated to form the activated polymer of this invention as described above, having at least one terminal reactive moiety.
  • the terminal reactive moiety may vary depending on the reactivity of a target moiety on the biologically active agent to be conjugated. Examples of reactive groups on proteins are thiols and amines, while on small molecule drugs, amines, alcohols, thiols, and carboxylic acids are common reactive gorups.
  • the conjugate is then formed by reacting the terminal reactive moiety of the activated polymer with the target moiety on the biologically active agent. Such methods are well known in the art, and are discussed in the patents and publications referred to above in the context of forming terminal reactive moieties.
  • the polymer of this invention used for forming a conjugate is a poly(ether carbonate) composed of alkylene oxide oligomers, more preferably ethylene oxide oligomers, linked together by carbonate linkages.
  • Ethylene oxide oligomers are poly(ethylene glycol)s with a predetermined molecular weight, typically from about 88 to about 8000, preferably from about 88 to about 2000.
  • the polymer behaves in a similar manner as polyethylene glycol.
  • the polymer in the conjugate will break down into a number of smaller oligomer fragments. If the linkage between the polymer and the biologically active agent is stable, then, after degradation, one oligomer is linked to the agent.
  • a hydrolytically degradable hydrogel and method of making thereof are also provided.
  • a hydrogel typically is a polymeric network formed by crosslinking one or more multifunctional backbone molecules or polymers. The resulting polymeric network is hydrophilic and swells in an aqueous environment thus forming a gel-like material, i.e., hydrogel.
  • Hydrogels are useful for drug delivery as they can be implanted or injected into animal bodies.
  • a hydrogel comprises a backbone bonded to a crosslinking agent.
  • the polymer of this invention is used as the crosslinking agent in the hydrogel.
  • the polymer must be activated so that it has at least two terminal reactive moieties that are capable of reacting with multiple moieties on the backbone to form covalent linkages.
  • each activated polymer has one terminal reactive moiety capable of reacting with a moiety on the backbone, and another terminal reactive moiety capable of reacting with the corresponding terminal reactive moiety on the other type of activated polymer.
  • An example of this other moiety is, for example, a vinyl-containing group such as an acrylate group that can participate in chain polymerization among the different types of activated polymers.
  • the backbone of the hydrogel is a nontoxic biocompatible macromolecule or small molecule, having at least two or preferably more active groups available to react with the terminal reactive moieties of the crosslinking agent to form covalent linkages.
  • biocompatible it is intended that the molecule used as backbone would not substantially adversely affect the body and tissue of the living subject into which the hydrogel is to be implanted or injected. More particularly, the material does not substantially adversely affect the growth and any other desired characteristics of the tissue cells surrounding the implanted hydrogel. It is also intended that the material used does not cause any substantially medically undesirable effect in any other parts of the living subject.
  • the molecule is degradable inside the body, the degradation products should also be substantially biocompatible as defined above. Generally, the methods for testing the biocompatibility of a material well known in the art.
  • Suitable backbones include, but are not limited to, proteins, modified proteins such as glycoproteins, phosphorylated proteins, acylated proteins, and chemically modified proteins, peptides, aminocarbohydrates, glycosaminoglycans, aminolipids, polyols, polythiols, polycarboxylic acids, polyamines such as dilysine, poly(vinylamine) and polylysine, poly(ethylene glycol) amines, pharmaceutical agents having at least two active groups, etc.
  • proteins include, but are not limited to, proteins, modified proteins such as glycoproteins, phosphorylated proteins, acylated proteins, and chemically modified proteins, peptides, aminocarbohydrates, glycosaminoglycans, aminolipids, polyols, polythiols, polycarboxylic acids, polyamines such as dilysine, poly(vinylamine) and polylysine, poly(ethylene glycol) amines, pharmaceutical agents having at least two active groups,
  • the backbone include, but are not limited to, branched PEG amines, fibrin, fibrinogen, thrombin, albumins, globulins, collagens, fibronectin, chitosan, and the like.
  • the backbone may also be microorganisms such as viral particles, bacterial or yeast cells, animal or human cells or tissues.
  • the activated polymer of this invention used as a crosslinking agent can be in a linear, branched or star form.
  • three or more linear polymers are covalently linked, at one terminus, to a central, branched core moiety.
  • the central branch core moiety can be derived from the amino acid lysine, or polyols such as glycerol, pentaerythritol and sorbitol.
  • Branched PEGs are known in the art. These branched PEGs can be incorporated as components of the poly(ether carbonate)s of this invention.
  • the hydrogel of this invention is hydrolytically degradable.
  • the linkages between the backbones and the crosslinking agents formed from the crosslinking reactions can also be made hydrolyzable, by methods described in the context of the conjugate of this invention.
  • the hydrogel of this invention can gradually break down or degrade in the body as a result of the hydrolysis of the hydrolytically degradable linkages.
  • the hydrogel of this invention is suitable as a biomedical material and a carrier for the delivery of biologically active agents.
  • the hydrogel can carry therapeutic drugs and can be implanted or injected in the target area of the body.
  • the hydrogel may also carry other agents such as nutrients or labeling agents for imaging analysis.
  • a hydrogel containing a biologically active agent is termed herein as “a delivery system”.
  • the biologically active agents to be delivered can be used as the backbone, or part of the backbone of the hydrogel.
  • biologically active agents can be “hinged” to the hydrogel through a polymer of this invention or a linker molecule with one terminus of the polymer or the linker linked to the biologically active agent, and the other being connected through a covalent linkage to the hydrogel.
  • biologically active agents or other substances to be delivered can also be loaded into the hydrogel during the formation of the hydrogel, or afterwards by, for example, diffusion into the matrix of the hydrogel without being covalently bonded to the hydrogel structure.
  • the hydrogel can be substantially water swellable.
  • the degradation or breakdown of the hydrogel in the body is gradual in nature and subject to control because of the hydrolytically degradable carbonate linkages in the crosslinking agents.
  • the hydrogels of the invention are particularly useful for sustained release of a biologically active agent or other substance in the body.
  • the hydrogels have potential utility for adhesion prevention, bioadhesives, surgical sealants, and related surgical applications.
  • the product was precipitated with 500 ml of isopropanol, stirred for half hour, then collected by vacuum filtration. The collected product was washed with isopropanol 200 ml ⁇ 2), and dried in vacuo overnight.
  • the resulting polymer was about 97% pure by gpc and nmr and had a molecular weight of 7000 Da.
  • HO-PEC 7 KDa -OH (10 g) (prepared in Example 2) in toluene (200 ml) was dried by azeotropic distillation and triethylamine (1.75 ml) in CH 2 Cl 2 was added. The resulting solution was cooled to 0° C. and acryloyl chloride (2.5 ml) was added under argon. After the addition was complete, the mixture was stirred overnight at room temperature. The resulting solution was concentrated, filtered, and the product precipitated from the filtrate by addition of ethyl ether (300 ml).
  • PEC 7 KDa diacrylate 100 mg was dissolved in 1 ml of pH 7 buffer and 30 ul of potassium persulfate was added. To the resulting solution was added 30 ⁇ l of 100 mM iron(II) sulfate solution. The solution was shaken and a hydrogel formed in several minutes.
  • NS—O 2 C—O-PEC 7 KDa -O—CO 2 —NS 300 mg was mixed with 3 ml of a 1 wt. % solution of chitosan at pH 4. The resulting solution formed a clear, firm hydrogel within 2 hours.
  • the dry product was placed in a 500 ml Parr bottle and dissolved in 100 ml of anhydrous 1,4-dioxane. 11.0 g of Pd/C (10% pd by wt.) was added and the bottle pressurized with 45 psi of hydrogen and shaken for 20.5 hours. The mixture was filtered to remove the Pd/C and the solvent removed by rotary evaporation. The crude solid was precipitated by adding 500 ml of isopropyl alcohol. The product was collected by filtration and dried under vacuum. The product was demonstrated to be greater than 98% pure with a polydispersity of 1.034 by GPC.

Abstract

A water soluble polymer is provided having two or more oligomers linked to each other by hydrolytically degradable carbonate linkages. The polymer can be hydrolytically degraded into oligomers (e.g., oligomers of ethylene oxide) under physiological conditions. The polymer can be conjugated to biologically active agents such as proteins or peptides to impart improved water solubility, reduced immunogenicity, reduced rate of renal clearance, and increased stability. The polymer is useful in making hydrolytically degradable hydrogels which can be used in drug delivery and related biomedical applications. On example of the polymer is a poly(ether carbonate) of the formula X—O—[(—CH2CH2—O—)n—CO2—]n(CH2CH2))n-y where X and Y are independently H, alkyl, alkenyl, aryl, or a reactive moiety, and at least one of X and Y is a reactive moiety.

Description

    FIELD OF THE INVENTION
  • This invention generally relates to water soluble, hydrolytically degradable, and nonpeptidic polymers, and particularly to polymers and gels therefrom that are suitable for medical devices, drug enhancement and in vivo delivery of biologically active agents. [0001]
  • BACKGROUND OF THE INVENTION
  • Conjugation of agents having a known or potential therapeutic benefit to water soluble, non-immunogenic polymers can impart to the agent desirable characteristics including, among others, improved solubility, greater stability, and reduced immunogenicity. It has become increasingly important in the pharmaceutical industry to develop conjugates having these characteristics so as to increase the number of options for therapeutic benefit. [0002]
  • An example of a polymer that can be used to develop conjugates with therapeutic agents is poly(ethylene glycol) (“PEG”). Therapeutic agents conjugated to PEG are sometimes said to be “PEGylated.” Several PEGylated therapeutics have been developed that exhibit enhanced water solubility, longer circulation lifetimes, and lower immunogenicity as compared to the unconjugated therapeutic agent. Because of the rapid motion and heavy hydration of the polymer, PEGs usually are of much higher apparent molecular weight than the therapeutics to which they are attached. Thus, they tend to mask the therapeutic agent from the immune system and to preclude excretion through kidneys. [0003]
  • The term PEG is commonly used to describe any of a series of polymers having the general formula HO—(CH[0004] 2CH2—O)n—H, where “n” represents the number of ethylene oxide monomers in the polymer. However, the parent polymer is generally unsuitable for attachment to a therapeutic agent. Hydroxyl groups are relatively unreactive toward groups commonly present on therapeutic agents and thus PEG normally has to be “activated” by converting at least one end hydroxyl group into a more reactive form. It is also usually important to activate the PEG polymer with a terminal group that is selective in its reactions. For example, several PEG derivatives have been developed that are more likely to react with amine groups. Others have been developed that preferentially react with thiol groups.
  • Successful PEG derivatives may have to meet a number of requirements, depending on the specific application. For conjugation to proteins, the PEG derivative should usually have a desirable and suitably selective reactivity at physiologic conditions of temperature, pressure, and pH to preserve the activity of the unconjugated protein. In some circumstances, it is desirable to cleave the PEG polymer from the therapeutic agent at some point after the agent is delivered in vivo. [0005]
  • Some PEG derivatives have been used in combination with other polymers to prepare insoluble gels in which drugs can be entrapped or chemically bound. For example, Sawhney et al., [0006] Macromolecules, 26:581 (1993) describes the preparation of block copolymers of PEG with polyglycolide or polylactide blocks at both ends of the PEG chain. The copolymers are then activated by terminal substitution with acrylate groups, as shown below.
  • CH2═CH—CO—(O—CH2—CO)n—O-PEG-O—(CO—CH2—O)n—CO—CH═CH2
  • In the above formula, the glycolide blocks are the —O—CH[0007] 2—CO— units. The addition of a methyl group to the methylene gives a lactide block; n can be multiples of 2. Vinyl polymerization of the acrylate groups produces an insoluble, crosslinked gel with a polyethylene backbone.
  • The polylactide or polyglycolide segments of the polymer backbone shown above, which are ester groups, are susceptible to slow hydrolytic breakdown, with the result that the crosslinked gel undergoes slow degradation and dissolution. The hydrogel degrades in vivo and can result in non-PEG components being released into the blood stream, which can be undesirable. [0008]
  • It is desirable to develop improved polymers providing additional choices for use in drug delivery and other applications. [0009]
  • SUMMARY OF THE INVENTION
  • This invention provides a water soluble, nonpeptidic polymer having two or more oligomers linked together by hydrolytically degradable carbonate linkages. The polymer can be hydrolytically degraded into small oligomers in an aqueous environment, including in vivo conditions. The polymer is easy to prepare and the molecular weight of the oligomers resulting from polymer degradation can be easily controlled, which can be desirable for some applications. The polymer can be conjugated to a biologically active agent such as a protein or peptide. The polymer can impart desirable characteristics to the conjugates of improved water solubility and reduced immunogenicity. The polymer is useful for preparing insoluble cross linked structures, including hydrogels, that are hydrolytically degradable into soluble polymers of predetermined molecular weight. [0010]
  • The oligomers are alkylene oxide oligomers. Typically, the oligomers are ethylene oxide oligomers, and the polymer is a poly(ether carbonate) having the formula of: [0011]
  • HO—[(—CH2CH2—O)n—CO2]m—(—CH2CH2—O)nH
  • where n is from about 1 to 2,000, normally from 2 to 2,000, and m is from about 2 to 200. Since carbonate linkages are hydrolytically degradable under mild conditions, the polymer will hydrolyze to produce oligomer fragments of much lower molecular weight than the starting polymer: [0012]
  • HO—[(—CH2CH2—O)n—CO2]m—(—CH2CH2—O)nH+(m+1)H2O→(m+1)HO—(—CH2CH2—O—)n—H+mCO2
  • In addition to providing many of the desirable features of other polymers, including poly(ethylene glycol) as described above, this new polymer can degrade in the body and thus facilitates removal of the polymer from the body. The degradation products are themselves normally nontoxic small PEGs that typically are rapidly cleared from the body. [0013]
  • The polymer can be prepared in a number of ways. In one embodiment of this invention, the poly(ether carbonate) is prepared by polymerizing an activated oligomer having the formula of: [0014]
  • HO—(—CH2CH2—O—)n—CO2-Z
  • where n can be from about 2 to 2000 and Z is a reactive leaving group such as N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl. [0015]
  • The polymer can be prepared by polymerizing ethylene oxide oligomers of the formula: [0016]
  • HO—(—CH2CH2—O—)n—H
  • where n can be from about 2 to 2000 with an activating molecule of Z-O—CO[0017] 2-Z, where Z is as described.
  • Alternatively, the ethylene oxide oligomer [0018]
  • HO—(—CH2CH2—O—)n—H
  • can be polymerized with a bifunctional ethylene oxide oligomer: [0019]
  • Z-OCO2—(—CH2CH2—O—)n—CO2-Z
  • where n and Z are as described above, to form the poly(ether carbonate). [0020]
  • The polymerization reactions may be conducted either in an organic solvent or in a melt, in the presence of an organic base. Examples of suitable solvents include acetonitrile, THF, dimethylformamide, dimethylsulfoxide, benzene, toluene, the xylenes, chloroform, and methylene chloride. Examples of suitable organic bases include triethylamine, pyridine, quinoline, 4,4-dimethylaminopyridine and triethylamine. The polymerization reactions can be conducted at a temperature of from about 37° C. to 100° C., typically from about 45° C. to 100° C., and advantageously from about 70° C. to 90° C. [0021]
  • The polymer of this invention can be modified at one termius with alkyl or aryl groups to make one end of the polymer inert. The polymer can be activated at one or more of its termini to form a terminal reactive moiety. Thus, a modified or activated poly(ether carbonate) of this invention can be represented as: [0022]
  • X—O—[(CH2CH2—O)n—CO2]m—(CH2CH2—O)n—Y
  • where m and n are as defined above, and where X and Y can independently be H, alkyl, alkenyl, aryl, and reactive terminal moieties, including N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, or others. Alternatively, X and Y can include linker groups terminating in active groups such as aldehyde N-maleimidyl or —S—S-ortho-pyridyl. A wide variety of activating groups and linkers can be used. [0023]
  • The activated polymer of this invention can be reacted with an active group on a biologically active agent, such as a protein or peptide, to form a conjugate. For example, N-succinimidyloxy, 1-benzotriazolyloxy, and p-nitrophenyloxy are leaving groups suitable for the formation of a carbamate linkage between the polymer and a biologically active agent having an amino group. Thus proteins, peptides, amino drugs, or amino carbohydrates can be linked to such activated polymers. For example, when X is H, and Y is N-succinimidyloxycarbonyl, a conjugate can be formed of the following formula: [0024]
  • HO—[(CH2CH2—O)n—CO2]m—(CH2CH2—O)n—CONH-Protein
  • When a protein to be conjugated has an accessible thiol group, the polymer of this invention can be activated to contain a terminal reactive moiety that is reactive with thiol, including, for example, iodoacetamide, vinylsulfone, maleimide, or S—S-ortho-pyridyl, which moiety is then reacted with the thiol group to form a thiol site-specific conjugate of the protein. [0025]
  • When the polymer of this invention is activated at two termini, it can be used as a crosslinking agent to crosslink a multifunctional molecule to form a hydrolytically degradable hydrogel. Examples of multifunctional molecules suitable as “backbones” in formation of hydrogels include proteins such as collagen, aminocarbohydrates such as chitosan, polyamines such as polylysine and poly(vinylamine), and multi-armed or branched poly(ethylene glycol) amines. The hydrogels of this invention are useful in many biomedical applications such as drug delivery, surgical adhesion prevention, wound and scar healing, bioadhesives and surgical implants. [0026]
  • In another embodiment, the polymer of this invention can be activated by attachment of terminal vinyl groups. This activated polymer can be self-polymerized in the presence of a conventional vinyl polymerization catalyst to form a hydrolytically degradable hydrogel. [0027]
  • Thus, this invention provides a versatile polymer that is especially suited for conjugating to a biologically active agent and for forming a hydrogel. The polymer is easy to prepare and can be synthesized in large quantities. The polymer can be formed in a single reaction with multiple degradable carbonate linkages in the backbone. The conjugate and hydrogel of this invention can be degraded under physiological conditions. The degradation generates oligomers of predetermined molecular weight that can be easily cleared from the body. [0028]
  • The foregoing and other advantages and features of the invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying examples, which illustrate preferred and exemplary embodiments. [0029]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The invention will now be described more fully hereinafter with reference to the accompanying examples, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. [0030]
  • As used herein, the term “polymer” means a molecule, formed by the chemical union of two or more oligomer units. The chemical units are normally linked together by covalent linkages. The two or more combining units in a polymer can be all the same, in which case the polymer is referred to as a homopolymer. They can be also be different and, thus, the polymer will be a combination of the different units. These polymers are referred to as copolymers. [0031]
  • The term “oligomer” is used herein to mean a molecule, typically an organic molecule, which in itself is formed by the chemical union of two or more monomer units. The monomer units of an oligomer may be different or all the same. An oligomer is capable of reacting with another oligomer which is same or different, in a polymerization reaction to form a polymer. As used herein, the term oligomer by no means limits the size of the molecule or the number of combining units or monomers in the oligomer. Rather, “oligomer” is used to indicate a unit for forming a polymer of the invention. The structure of an oligomer in a polymer may be somewhat different in chemical structure from the oligomer prior to polymerization because of the polymerization reaction and the formation of covalent linkages. [0032]
  • The term “carbonate linkage” is used herein to mean a linkage that includes the group —O—CO[0033] 2—. It is to be understood that a carbonate linkage is distinct from a carboxylate linkage which typically has a structure of R—CO2— (where n is at least 1 and R=alkyl or aryl) and has different chemical and physical properties.
  • The terms “group,” and “moiety,” are all used herein interchangeably to refer to a distinct, definable portion or unit of a molecule. Sometimes, the structure of a group or moiety may include another smaller group or moiety. For example, a functional group of —O—CO[0034] 2-Z includes Z which may be a reactive group or moiety including N-succinimidyl or 1-benzotriazolyl.
  • The terms “active,” “reactive,” and “functional” are used herein interchangeably to mean that a molecule or a group or moiety is reactive with other molecules or groups or moieties of molecules. [0035]
  • The term “biologically active agent” when used herein means any substance that can impact any physical or biochemical properties of a biological organism including, but not limited to, viruses, bacteria, fungi, plants, animals and humans. In particular, as used herein, a biologically active agent can be any substance intended for the diagnosis, cure, mitigation, treatment, or prevention of a disease in humans or other animals, or to otherwise enhance the physical or mental well being of humans or animals. Examples of biologically active agents include, but are not limited to, organic and inorganic compounds, proteins, peptides, lipids, polysaccharides, nucleotides, DNAs, RNAs, other polymers, and derivatives thereof. Examples of biologically active agents include antibiotics, fungicides, anti-viral agents, anti-inflammatory agents, anti-tumor agents, cardiovascular agents, anti-anxiety agents, hormones, growth factors, steroidal agents, and the like. Biologically active agents include microorganisms such as bacteria and yeast cells, viral particles, plant or animal or human cells or tissues, and the like, in their native or modified forms. [0036]
  • The oligomers used in the practice of the invention should be selected so that they and the degradation products of the polymer of this invention are water soluble and can easily be excreted from animal bodies under natural physiological conditions. They should be non-toxic, or at least of acceptable low toxicity, and should not cause a substantial adverse effect in human or animal bodies. [0037]
  • Many different types of alkylene oxide oligomers are useful in forming the polymer of this invention. In its simplest form, an alkylene oxide “homo-oligomer” is used having the formula of HO—(—CHRCH[0038] 2—O)n—H, where R is H or an alkyl, including methyl. Suitable oligomers also include alkylene oxide “co-oligomers,” which are composed of different alkylene oxide monomers in which R is varied independently along the chain. An example of a co-oligomer is a structure in which two different R groups are present in a block such as HO—(—CHR1CH2—O—)n—(—CHR2CH2—O—)m—H, where n and m can be varied independently. An example of this type of block structure is the case in which R1 is hydrogen and R2 is methyl.
  • Block oligomers can exhibit surface activity. Degradable surfactants are useful in drug delivery systems and can be used to form micelles and thermally reversible gels. Random oligomers in which R[0039] 1 and R2 are randomly placed along the oligomer chain are also useful. The oligomers can be branched, as in the formula
  • R3[O—(—CHR1CH2—O—)n—]mH
  • where R[0040] 3 is a core branching moiety, including glycerol or pentaerythritol, R1 is alkyl, n can range from 2 to hundreds, and m is at least 3.
  • A suitable oligomer can be formed from about 2 to 2000 monomers. However, the size of the oligomers used can vary so long as the above requirements are met. Normally an oligomer has from about 5 to 500 monomers. Advantageously, an oligomer has from about 10 to 50 monomers. An oligomer can be prepared by polymerizing or co-polymerizing monomers, and the size or molecular weight of the oligomer can be controlled by limiting the extent of this polymerization reaction. [0041]
  • As noted above, the oligomers contained in the polymer of this invention can be the same or different types of oligomers, or oligomers of the same type but different sizes. Therefore, the polymer of this invention can be either a homopolymer or heteropolymer. [0042]
  • The polymer of this invention typically has one single linear polymer backbone with two termini. However, branched polymers and star polymers are also contemplated that have two or more linear polymers, at least one of which is the linear polymer backbone of this invention, covalently linked to a central branching core. [0043]
  • The polymer of this invention can have an inert terminal moiety, typically H, alkyl, and aryl. The alkyl and aryl groups can be substituted or unsubstituted, and normally are methyl, ethyl, phenyl, etc. The polymer can also have one or more reactive moieties capable of reacting with a moiety in another molecule, such as an amino group or a thiol group on a protein. Examples of such reactive moieties include, but are not limited to, acryloyl, alkenyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, o-pyridyldithiyl, and the like. [0044]
  • In one embodiment of this invention, the hydrolytically degradable polymer is a poly(ether carbonate) composed of two or more alkylene oxide oligomers and/or alkylene oxide monomers covalently linked together by carbonate linkages. For example, the poly(ether carbonate) can have the formula of [0045]
  • X—O—{[(R1—O)a—CO2—]h—[(R2—O)b—CO2—]i}m—{[(R3—O)c—CO2—]j—[(R4—O)d—CO2—]k}—(R5—O)e—Y
  • wherein [0046]
  • R[0047] 1, R2, R3, R4, and R5 are alkyl groups which may be linear, branched, substituted or unsubstituted, and they can be same or different; typically R1, R2, R3, R4, and R5 are ethyl;
  • a, b, c, d, e each is an integer of from 1 to about 2000, normally from about 5 to 500, and advantageously from about 10 to 50; [0048]
  • h, i, j, and k each is an integer of from 0 to about 100, and the sum of h, i, j, and k is from about 2 to 200, normally from about 5 to 100, and advantageously from about 10 to 50; and [0049]
  • each of X and Y is hydrogen, alkyl, alkenyl, aryl, or reactive moieties as described above, and X and Y can be same or different. [0050]
  • In a preferred embodiment, the poly(ether carbonate) of this invention has the formula of: [0051]
  • X—O—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—Y
  • wherein n is an integer of from about 2 to 2000, normally from about 5 to 500, and advantageously from about 10 to 50; m is an integer of from about 2 to 100, typically from about 5 to 100, and advantageously from about 10 to 50, and wherein X and Y can be same or different and each independently is H, alkyl, alkenyl, aryl, or a reactive moiety, acryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl. [0052]
  • This specific form of poly(ether carbonate) contains repeating ethylene oxide oligomers linked by carbonate linkages that can be hydrolytically cleaved. Such hydrolytic cleavage leads to ethylene oxide oligomers and carbon dioxide. Therefore, the poly(ether carbonate) differs substantially from poly(ethylene glycol) or PEG in having multiple degradable backbone carbonate linkages that allow the polymer to be broken down into many smaller oligomers. Since the rate of degradation of the polymer is proportional to the number of degradable carbonate linkages present, and since the size and number of the oligomers can be predetermined, substantial control over both degradation rate and the size of the degradation products is thus possible. [0053]
  • To prepare polymers of the invention, in one example, one or more oligomers as described above are provided each having a hydroxyl group at one terminus and a functional group of —O—CO[0054] 2-Z at another terminus. The oligomers are then polymerized or co-polymerized in a condensation polymerization reaction under conditions sufficient to form a hydrolytically degradable polymer.
  • The functional group —O—CO[0055] 2-Z is capable of reacting with a hydroxyl group to form a carbonate linkage. Typically, Z can be any reactive leaving groups so long as the functional group can react with a hydroxyl group to form a carbonate linkage. Examples of suitable leaving groups include N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl. Methods for preparing an oligomer having a functional group —O—CO2-Z as described above are well known in the art, and are disclosed in U.S. Pat. Nos. 5,650,234, 5,281,698 and 5,468,478; Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem. Biotech., 27:45 (1991), all of which are incorporated herein by reference.
  • As discussed above, one or more types of oligomers can be polymerized together. In addition, if desired, monomers having a hydroxyl terminus and a functional group —O—CO[0056] 2-Z at another terminus, can also be included in the polymerization mixture.
  • Thus, to give an example, the poly(ether carbonate) [0057]
  • HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
  • as described above can be prepared in accordance with this method by the following steps. First, an ethylene oxide oligomer is provided having a formula of HO—(—CH[0058] 2CH2—O—)n—O—CO2-Z, where Z is a reactive leaving group such as N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl. This oligomer is then polymerized under controlled conditions to provide the above poly(ether carbonate).
  • In another example of this invention, a first oligomer is provided, which is a bifunctional oligomer having a first functional group of —O—CO[0059] 2—W at one terminus and, at another terminus, a second functional group of —O—CO2-Z. Both functional groups are capable of reacting with a hydroxyl group to form a carbonate linkage. Z and W are reactive leaving groups, and can be any leaving groups known in the art so long as the functional groups containing them, as stated above, are capable of reacting with a hydroxyl group to form a carbonate linkage. Z and W can be same or different. The preferred Z and W are N-succinimidyl, 1-benzotriazolyl, and p-nitrophenyl. Two or more different bifunctional oligomers can also be used in the same polymerization reaction.
  • Methods for preparing such bifunctional oligomers are similar to those for making the monofunctional oligomers described above. Preferably, Z and W are the same, and the bifunctional molecule Z-oligomer-Z can be provided by activating an oligomer having two hydroxyl terminal groups, with an activating molecule having the formula of Z-O—CO[0060] 2-Z. Suitable examples of the activating molecule include, disuccinimidylcarbonate, bis(1-benzotriazolyl) carbonate and bis(p-nitrophenyl) carbonate. See, e.g., U.S. Pat. Nos. 5,281,698; 5,650,234; Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem. Biotech., 27:45 (1991), all of which are incorporated herein by reference.
  • In addition to the first oligomer that is bifunctional, a second oligomer is also provided having two terminal hydroxyl groups. This second oligomer is then polymerized with the first oligomer to form the polymer of this invention. [0061]
  • Two or more types of bifunctional oligomers can be used in the same polymerization reaction. In addition, two or more types of oligomers having two terminal hydroxyl groups can also be used in a polymerization reaction. As will be apparent to a skilled artisan, when only one type of bifunctional oligomer and one type of dihydroxyl oligomer are used, and when the two oligomers are the same except for the terminal groups, the polymer formed therefrom will be a homopolymer having a single type of repeating unit or oligomer linked with hydrolytically degradable linkages. Otherwise, a heteropolymer or block polymer or terpolymer will be made containing different types of oligomers in the polymer backbone. [0062]
  • To give an example of the method of this embodiment, the poly(ether carbonate) [0063]
  • HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
  • can be prepared by co-polymerizing a first ethylene oxide oligomer having a formula of [0064]
  • Z-O2C—O—(—CH2CH2—O—)n—CO2-Z
  • and a second ethylene oxide oligomer HO—(—CH[0065] 2CH2—O—)n—OH, under suitable polymerization conditions. Z is preferably N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl. The oligomer
  • Z-O2C—O—(—CH2CH2—O—)n—CO2-Z
  • can be prepared by reacting Z-O—CO[0066] 2-Z with HO—(—CH2CH2—O—)n—OH, under the conditions disclosed in U.S. Pat. No. 5,281,698.
  • In yet another method, one or more oligomers having two hydroxyl terminal groups are polymerized directly with an activating molecule having the formula of Z-O—CO[0067] 2-Z to form the hydrolytically degradable polymer. Thus, for example, the poly(ether carbonate)
  • HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
  • can also be prepared by co-polymerizing an activating molecule Z-O—CO[0068] 2-Z and the oligomer HO—(—CH2CH2—O—)n—OH, under conditions sufficient to form the poly(ether carbonate).
  • Again, in this method, either one oligomer is used to generate a homopolymer, or two or more different oligomers can be used in the same polymerization reaction to produce a heteropolymer, or block polymer or terpolymer. [0069]
  • The polymerization reactions are conducted under conditions sufficient to form the hydrolytically degradable polymer of this invention. The polymerization reaction in each of the above-described methods is a condensation reaction. Many different known reaction conditions can be used. Typically, a catalyst is included in the polymerization reaction mixture. Examples of suitable catalysts are organic bases, including triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine. Amine bases such as 4,4-dimethylaminopyridine and triethylamine are preferred. [0070]
  • The polymerization can be conducted in either melt or solvent. Suitable solvents include, but are not limited to, acetonitrile, THF, dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes, chloroform, and methylene chloride. The polymerization reaction rate and the extent of polymerization, which determines the average molecule weight of the final hydrolytically degradable polymer product can be partly controlled by the reaction temperature and the reaction time. Suitable reaction temperature can vary from about 0° C. to 100° C. Higher reaction temperatures lead to greater reaction speed. Preferably, the polymerization reaction is conducted at a temperature of from about 37° C. to 100° C., typically from about 45° C. to 100° C. and advantageously from about 70° C. to 90° C. When the reaction is conducted in a melt, the temperature needs be maintained at a certain minimum temperature in order to keep the reaction mixture at a melt state. [0071]
  • In the above described three embodiments of the method of this invention, the polymerization reactions would be predicted to lead to polymers with an activated carbonate terminal group. In practice, however, NMR analysis of the polymer products indicates that the terminal groups of the hydrolytically degradable polymer prepared therefrom often are hydroxyl groups. While not wishing to be bound by any theory, it is believed that this is caused by reaction with a small amount of water present as an impurity in the reaction. Any small amount of remaining terminally activated carbonate may be removed by hydrolyis in water for a short period or near a neutral pH. The terminal activating groups are much more sensitive to water than are the degradable carbonate linkages. [0072]
  • The polymer of this invention can optionally be activated at one or all termini, thus providing an activated polymer capable of being covalently linked to another molecule, including, for example, a protein, to form a conjugate. The polymer can also be capped at one terminus by an inert group and at another terminus by a reactive moiety. [0073]
  • The polymer of this invention can be activated at its terminus to form a terminal reactive moiety by methods well known to those familiar with the art of organic or polymer chemistry. The well established methods in the broad field of poly(ethylene glycol) chemistry are generally useful, and such methods should be apparent to a skilled artisan. The polymer can be activated at one terminus, or all termini, in which case, the reactive moieties at different termini can be same or different. [0074]
  • For example, the polymer may be activated to form a terminal moiety of N-succinimidyl carbonate (see e.g., U.S. Pat. Nos. 5,281,698, 5,468,478), amine (see, e.g., Buckmann et al. [0075] Makromol. Chem. 182:1379 (1981), Zaplipsky et al. Eur. Polym. J. 19:1177 (1983)), hydrazide (See, e.g., Andresz et al. Makromol. Chem. 179:301 (1978)), succinimidyl propionate and succinimidyl butanoate (see, e.g., Olson et al. in Poly(ethylene glycol) Chemistry & Biological Applications, pp 170-181, Harris & Zaplipsky Eds., ACS, Washington, D.C., 1997; see also U.S. Pat. No. 5,672,662), succinimidyl succinate (See, e.g., Abuchowski et al. Cancer Biochem. Biophys. 7:175 (1984) and Joppich et al. Macrolol. Chem. 180:1381 (1979), succinimidyl ester (see, e.g., U.S. Pat. No. 4,670,417), benzotriazole carbonate (see, e.g., U.S. Pat. No. 5,650,234), glycidyl ether (see, e.g., Pitha et al. Eur. J. Biochem. 94:11 (1979), Elling et al., Biotech. Appl. Biochem. 13:354 (1991), oxycarbonylimidazole (see, e.g., Beauchamp, et al., Anal. Biochem. 131:25 (1983), Tondelli et al. J. Controlled Release 1:251 (1985)), p-nitrophenyl carbonate (see, e.g., Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem. Biotech., 27:45 (1991)), aldehyde (see, e.g., Harris et al. J. Polym. Sci. Chem. Ed. 22:341 (1984), U.S. Pat. Nos. 5,824,784, 5,252,714), maleimide (see, e.g., Goodson et al. Bio/Technology 8:343 (1990), Romani et al. in Chemistry of Peptides and Proteins 2:29 (1984)), and Kogan, Synthetic Comm. 22:2417 (1992)), orthopyridyl-disulfide (see, e.g., Woghiren, et al. Bioconj. Chem. 4:314 (1993)), acrylol (see, e.g., Sawhney et al., Macromolecules, 26:581 (1993)), vinylsulfone (see, e.g., U.S. Pat. No. 5,900,461). In addition, two molecules of the polymer of this invention can also be linked to the amino acid lysine to form a di-substituted lysine, which can then be further activated with N-hydroxysuccinimide to form an active of N-succinimidyl moiety (see, e.g., U.S. Pat. No. 5,932,462). All of the above references are incorporated herein by reference.
  • To give an example, the polymer of this invention may be activated to form a terminal reactive moiety of N-succinimidyl carbonate or 1-benzotriazolyl carbonate by reacting the polymer with di-N-succinimidyl carbonate or di-1-benzotriazolyl carbonate respectively. To give another example, terminal reactive moieties such as N-maleimidyl and o-pyridyldithiyl may be prepared by reacting the polymer with activated carbonates connected to N-maleimidyl or o-pyridyldithiyl by linker groups. Terminal aldehyde and acetal moieties can be attached by linking groups. Terminal acid groups can be attached by reaction of the above active carbonates with amino acids or other acid linkers. These acids can then be activated by formation of active esters such as succinimidyl active esters. [0076]
  • The polymer of this invention, activated or not, as prepared by the above methods, can be easily purified from the reaction mixture. Many methods known in the art can be used. A preferred method for purifying the polymer and its derivatives is by precipitation from a solvent in which they are essentially insoluble while the reactants are soluble. Suitable solvents include ethyl ether or isopropanol. As is apparent to a skilled artisan, other methods such as ion exchange, size exclusion, silica gel, and reverse phase chromatography can also be useful. [0077]
  • In accordance with another aspect of this invention, the activated polymer is used to form a conjugate with a biologically active agent. The conjugate comprises the polymer of this invention covalently linked to a biologically active agent. Because the polymer of this invention is hydrolytically degradable in vivo and can be cleaved at the carbonate linkages, thus forming smaller oligomers, the conjugate is especially useful for controlled delivery of the bound agent into animal bodies. Since the polymer in the conjugate is susceptible to breakdown into smaller oligomers, the polymer typically is excreted from animal bodies faster than a polymer of similar size that is not degradable. Thus, potential adverse effects that may be caused by a large polymer's long period of stay in the body is avoided. Therefore, conjugation of the polymer of this invention to a biologically active agent can provide for a sufficient circulation period for the agent while minimizing any adverse effects of the polymer. [0078]
  • In the conjugates of this invention, the linkage between the biologically active agent and the polymer of this invention can be stable or hydrolytically degradable. When it is degradable, substantially all of the polymer can be cleaved off the biologically active agent under physiological conditions, releasing the agent substantially in its native form inside the body. Methods for forming a hydrolytically degradable linkage between a biologically active agent and a water soluble polymer are well known in the art and should be apparent to a skilled artisan. For example, ester linkages formed by the reaction of PEG carboxylic acids or activated PEG carboxylic acids with alcohol groups on a biologically active agent generally hydrolyze under physiological conditions to release the agent. Other hydrolytically degradable linkages include carbonate linkages; imine linkages resulted from reaction of an amine and an aldehyde (see, e.g., Ouchi et al., [0079] Polymer Preprints, 38(1):582-3 (1997), which is incorporated herein by reference.); phosphate ester linkages formed by reacting an alcohol with a phosphate group; hydrozone linkages which are reaction product of a hydrazide and an aldehyde; acetal linkages that are the reaction product of an aldehyde and an alcohol; orthoester linkages that are the reaction product of a formate and an alcohol; peptide linkages formed by an amine group, e.g., at an end of a polymer such as PEG, and a carboxyl group of a peptide; and oligonucleotide linkages formed by a phosphoramidite group, e.g., at the end of a polymer, and a 5′ hydroxyl group an oligonucleotide.
  • Methods for conjugating the polymer of this invention to a biologically active agent should be apparent based on the above discussion. Typically, the polymer of this invention must be activated to form the activated polymer of this invention as described above, having at least one terminal reactive moiety. The terminal reactive moiety may vary depending on the reactivity of a target moiety on the biologically active agent to be conjugated. Examples of reactive groups on proteins are thiols and amines, while on small molecule drugs, amines, alcohols, thiols, and carboxylic acids are common reactive gorups. The conjugate is then formed by reacting the terminal reactive moiety of the activated polymer with the target moiety on the biologically active agent. Such methods are well known in the art, and are discussed in the patents and publications referred to above in the context of forming terminal reactive moieties. [0080]
  • In a preferred embodiment, the polymer of this invention used for forming a conjugate is a poly(ether carbonate) composed of alkylene oxide oligomers, more preferably ethylene oxide oligomers, linked together by carbonate linkages. Ethylene oxide oligomers are poly(ethylene glycol)s with a predetermined molecular weight, typically from about 88 to about 8000, preferably from about 88 to about 2000. Thus, in this embodiment of the invention, the polymer behaves in a similar manner as polyethylene glycol. However, when delivered in vivo, the polymer in the conjugate will break down into a number of smaller oligomer fragments. If the linkage between the polymer and the biologically active agent is stable, then, after degradation, one oligomer is linked to the agent. [0081]
  • In accordance with another aspect of this invention, a hydrolytically degradable hydrogel and method of making thereof are also provided. As is known in the art, a hydrogel typically is a polymeric network formed by crosslinking one or more multifunctional backbone molecules or polymers. The resulting polymeric network is hydrophilic and swells in an aqueous environment thus forming a gel-like material, i.e., hydrogel. Hydrogels are useful for drug delivery as they can be implanted or injected into animal bodies. Typically a hydrogel comprises a backbone bonded to a crosslinking agent. [0082]
  • In accordance with this invention, the polymer of this invention is used as the crosslinking agent in the hydrogel. The polymer must be activated so that it has at least two terminal reactive moieties that are capable of reacting with multiple moieties on the backbone to form covalent linkages. [0083]
  • Alternatively, two or more types of activated polymer are used as crosslinking agents. Each activated polymer has one terminal reactive moiety capable of reacting with a moiety on the backbone, and another terminal reactive moiety capable of reacting with the corresponding terminal reactive moiety on the other type of activated polymer. An example of this other moiety is, for example, a vinyl-containing group such as an acrylate group that can participate in chain polymerization among the different types of activated polymers. When the polymer of this invention is activated so that it has two terminal vinyl groups, the polymer itself may act as both crosslinking agent and backbone, and self-polymerize into a hydrolytically degradable hydrogel through a chain polymerization reaction. [0084]
  • The backbone of the hydrogel is a nontoxic biocompatible macromolecule or small molecule, having at least two or preferably more active groups available to react with the terminal reactive moieties of the crosslinking agent to form covalent linkages. By “biocompatible” it is intended that the molecule used as backbone would not substantially adversely affect the body and tissue of the living subject into which the hydrogel is to be implanted or injected. More particularly, the material does not substantially adversely affect the growth and any other desired characteristics of the tissue cells surrounding the implanted hydrogel. It is also intended that the material used does not cause any substantially medically undesirable effect in any other parts of the living subject. In addition, if the molecule is degradable inside the body, the degradation products should also be substantially biocompatible as defined above. Generally, the methods for testing the biocompatibility of a material well known in the art. [0085]
  • Examples of suitable backbones include, but are not limited to, proteins, modified proteins such as glycoproteins, phosphorylated proteins, acylated proteins, and chemically modified proteins, peptides, aminocarbohydrates, glycosaminoglycans, aminolipids, polyols, polythiols, polycarboxylic acids, polyamines such as dilysine, poly(vinylamine) and polylysine, poly(ethylene glycol) amines, pharmaceutical agents having at least two active groups, etc. Specific examples of the backbone include, but are not limited to, branched PEG amines, fibrin, fibrinogen, thrombin, albumins, globulins, collagens, fibronectin, chitosan, and the like. In addition, the backbone may also be microorganisms such as viral particles, bacterial or yeast cells, animal or human cells or tissues. [0086]
  • The activated polymer of this invention used as a crosslinking agent can be in a linear, branched or star form. In branched or star forms, three or more linear polymers are covalently linked, at one terminus, to a central, branched core moiety. The central branch core moiety can be derived from the amino acid lysine, or polyols such as glycerol, pentaerythritol and sorbitol. Branched PEGs are known in the art. These branched PEGs can be incorporated as components of the poly(ether carbonate)s of this invention. [0087]
  • As will be apparent, because of the carbonate linkages incorporated in the crosslinking agent, the hydrogel of this invention is hydrolytically degradable. In addition, the linkages between the backbones and the crosslinking agents formed from the crosslinking reactions can also be made hydrolyzable, by methods described in the context of the conjugate of this invention. Thus, the hydrogel of this invention can gradually break down or degrade in the body as a result of the hydrolysis of the hydrolytically degradable linkages. [0088]
  • Therefore, the hydrogel of this invention is suitable as a biomedical material and a carrier for the delivery of biologically active agents. For example, the hydrogel can carry therapeutic drugs and can be implanted or injected in the target area of the body. The hydrogel may also carry other agents such as nutrients or labeling agents for imaging analysis. A hydrogel containing a biologically active agent is termed herein as “a delivery system”. [0089]
  • In the various applications of the hydrogel of this invention, the biologically active agents to be delivered can be used as the backbone, or part of the backbone of the hydrogel. Alternatively, biologically active agents can be “hinged” to the hydrogel through a polymer of this invention or a linker molecule with one terminus of the polymer or the linker linked to the biologically active agent, and the other being connected through a covalent linkage to the hydrogel. In addition, biologically active agents or other substances to be delivered can also be loaded into the hydrogel during the formation of the hydrogel, or afterwards by, for example, diffusion into the matrix of the hydrogel without being covalently bonded to the hydrogel structure. [0090]
  • Because the crosslinking agents (i.e., the polymers of this invention) in the hydrogel are water soluble, the hydrogel can be substantially water swellable. The degradation or breakdown of the hydrogel in the body is gradual in nature and subject to control because of the hydrolytically degradable carbonate linkages in the crosslinking agents. Thus, the hydrogels of the invention are particularly useful for sustained release of a biologically active agent or other substance in the body. The hydrogels have potential utility for adhesion prevention, bioadhesives, surgical sealants, and related surgical applications. [0091]
  • The present invention is further illustrated in the following examples which are given to illustrate the invention, but should not be considered in limitation of the invention.[0092]
  • EXAMPLE 1
  • Synthesis of HO-PEC[0093] 14 KDa-OH from HO—(—CH2CH2—O—)nCO2Bt (Bt=1-benzotriazolyl) (nave=23)
  • HO—(—CH[0094] 2CH2—O—)nCO2Bt (nave=23) (5 g) and 1.2 g of dimethylaminopyridine were dissolved in 10 ml of anhydrous acetonitrile . The reaction was stirred at 70° C. for 22 hours. The product was precipitated with 200 ml of isopropanol, stirred for one-half hour, then collected by vacuum filtration. The product was washed with isopropanol (100 ml×2), and dried in vacuo overnight. Yield: 4.1 g (82%). The resulting polymer was 99% pure by gpc analysis and had a molecular weight of 13,800 Da with a polydispersity of 1.47.
  • EXAMPLE 2
  • Synthesis of HO-PEC[0095] 7K-OH from Bt-O2C—(—O—CH2CH2—)n—OCO2-Bt and HO—(—CH2CH2—O—)n—H (nave=23)
  • 1. Preparation of Bt-O[0096] 2C—(O—CH2CH2—)n—OCO2-Bt (nave=23)
  • HO—(—CH[0097] 2CH2—O—)n—H (nave=23) (15 g, Aldrich) was dissolved in 100 ml of anhydrous acetonitrile, and solvent was removed by distillation. The residue was dissolved in 100 ml of anhydrous acetonitrile, and 13.3 g (1.5 equivalent) of di(1-benzotriazolyl carbonate) and 3.1 ml (1.3 equiv) of anhydrous pyridine were added. The reaction was stirred at room temperature under Ar overnight. The solvent was evaporated to dryness under reduced pressure. The product was precipitated by addition of 300 ml of cold diethyl ether. The precipitate was stirred under Ar for 30 min., collected by vacuum filtration and dried in vacuo overnight. There was 100% substitution by nmr analysis.
  • 2. Preparation of HO-PEC[0098] 7K-OH
  • HO—(—CH[0099] 2CH2—O—)n—H (nave=23) (Aldrich, 10 g) was dissolved in 50 ml of anhydrous acetonitrile and the solvent removed by distillation. The residue was dissolved in 20 ml of anhydrous acetonitrile and 10 g (1.0 equiv) of Bt-O2C—(—O—CH2CH2—)nOCO2-Bt (nave=23)- and 2.5 g of dimethyaminopyridine were added. The reaction was stirred at 70° C. for about 22 hours. The product was precipitated with 500 ml of isopropanol, stirred for half hour, then collected by vacuum filtration. The collected product was washed with isopropanol 200 ml×2), and dried in vacuo overnight. The resulting polymer was about 97% pure by gpc and nmr and had a molecular weight of 7000 Da.
  • EXAMPLE 3
  • Synthesis of bis-benzotriazolyl Carbonate of HO-PEC[0100] 7 KDa-OH
  • 15.0 g of HO-PEC[0101] 7 KDa-OH (prepared in Example 2) was dissolved in 50 ml of anhydrous acetonitrile, and solvent was distilled off. This process was repeated once. The residue was dissolved in 50 ml of anhydrous acetonitrile, and 1.8 g of bis(1-benzotriazolyl carbonate) and 0.5 ml of anhydrous pyridine were added. The reaction was stirred at room temperature under Ar overnight. The solvent was evaporated to dryness at reduced pressure and the product was precipitated by addition of 500 ml of isopropanol. The precipitate was stirred under Ar for 30 min., collected by vacuum filtration, and dried in vacuo overnight. Substitution was greater than 95% by nmr. Yield: 14.3 g.
  • EXAMPLE 4
  • Preparation of HO—[—(CH[0102] 2CH2O—)nCO2]m(—CH2CH2O)n—H (nave=45; mave=18 from HO(—CH2CH2O—)nCO2NS (nave=45) (NS=N-succinimidyl) in Solution
  • HO(—CH[0103] 2CH2O—)nCO2NS (nave=45) (5 g) was dissolved in acetonitrile (10 ml), dimethylaminopyridine (0.6 g) was added, and the resulting mixture was stirred at 70-80° C. overnight. Methylene chloride (20 ml) was added and the resulting mixture added to 600 ml of isopropyl alcohol. The resulting precipitate was collected by vacuum filtration and dried under vacuum overnight at room temperature. Nmr and gpc analysis indicated the polymer to have a molecular weight of 38,000 Da.
  • EXAMPLE 5
  • Preparation of HO-PEC[0104] 35 Kda-OH from HO(—CH2CH2O—) nCO2NS (nave=45) (NS=N-succinimidyl) in a Melt.
  • HO(—CH[0105] 2CH2O—)nCO2NS (nave=45) (5 g) and dimethylaminopyridine (0.6 g) were mixed and the resulting mixture was stirred at 80-90° C. overnight. Methylene chloride (20 ml) was added and the resulting mixture added to 600 ml of isopropyl alcohol. The resulting precipitate was collected by vacuum filtration and dried under vacuum overnight at room temperature. Nmr and gpc analysis indicated the polymer to have a molecular weight of 35,000 Da.
  • EXAMPLE 6
  • Preparation of HO-PEC[0106] 9.4 KDa-OH from HO—(—CH2CH2—O—)n—H(nave=14) and di(N-succinimidyl) carbonate
  • HO—(—CH[0107] 2CH2—O—)n—H (nave=14) (10.0 g) was dissolved in 100 ml of acetonitrile and the solution was dried by azeotropic distillation. After removal of acetonitrile, 80 ml of methylene chloride and 20 ml of acetonitrile, 2.7 ml of pyridine, and 4.3 g of di-(N-succinimidyl) carbonate were added. After stirring overnight, the solvent was removed under reduced pressure and 10 ml of acetonitrile and 4 g of DMAP were added. The mixture was stirred at 80-90° C. for 5 h and the product precipitated by addition of isopropanol. The product was collected by vacuum filtration and dried under vacuum at room temperature to obtain the product as a white powder (4.5 g). NMR and GPC analysis indicated that the polymer has a molecular weight of 9400 Da.
  • EXAMPLE 7
  • Preparation of Hydrogels from Bt-O[0108] 2C—O-PEC7 KDa-O—CO2-Bt and 8-arm-PEG amine (10 kDa)
  • In a test tube, 110 mg of Bt-O[0109] 2C—O-PEC7 KDa-O—CO2-Bt was dissolved in 1 ml of phosphate buffer (0.1 M, pH 7.0). To it was added 0.36 ml of 8-arm-PEG-amine (110 mg/ml in the buffer). After rapid shaking, it was allowed to sit. A hydrogel formed within 2 hours.
  • EXAMPLE 8
  • Degradation of the Hydrogel (Example 7) Prepared from PEC and 8-arm-PEG amine (10 kDa). [0110]
  • The hydrogel (0.5 g) was placed in 3 ml of PBS buffer or rat serum at 37° C. Rat serum was replaced with fresh serum every 10 to 12 hours. Gel disappearance was monitored visually. The gel prepared from PEC[0111] 7 KDa disappeared in PBS buffer within 3.5 days but in 1.5 days in rat serum, while the similar gel prepared from PEC3 Kda disappeared in PBS buffer in approximately 10 days.
  • EXAMPLE 9
  • Preparation of PEC[0112] 7 KDa Diacrylate
  • HO-PEC[0113] 7 KDa-OH (10 g) (prepared in Example 2) in toluene (200 ml) was dried by azeotropic distillation and triethylamine (1.75 ml) in CH2Cl2 was added. The resulting solution was cooled to 0° C. and acryloyl chloride (2.5 ml) was added under argon. After the addition was complete, the mixture was stirred overnight at room temperature. The resulting solution was concentrated, filtered, and the product precipitated from the filtrate by addition of ethyl ether (300 ml). The precipitate was collected by filtration, dissolved in 100 ml of methylene chloride, and the resulting solution stirred with 10 g of sodium carbonate overnight. The mixture was filtered and the product was precipitated with 500 ml of ethyl ether. The product was collected by filtration and dried under vacuum. NMR comparison of acrylate and backbone absorptions indicated approximately 100% of the terminal groups were acryloylated.
  • EXAMPLE 10
  • Preparation of Hydrogel from PEC[0114] 7 KDa Diacrylate
  • PEC[0115] 7 KDa diacrylate (100 mg) was dissolved in 1 ml of pH 7 buffer and 30 ul of potassium persulfate was added. To the resulting solution was added 30 μl of 100 mM iron(II) sulfate solution. The solution was shaken and a hydrogel formed in several minutes.
  • EXAMPLE 11
  • Preparation of Degradable Hydrogel from NS—O[0116] 2C—O-PEC7 KDa-O—CO2—NS and Chitosan
  • NS—O[0117] 2C—O-PEC7 KDa-O—CO2—NS (300 mg) was mixed with 3 ml of a 1 wt. % solution of chitosan at pH 4. The resulting solution formed a clear, firm hydrogel within 2 hours.
  • EXAMPLE 12
  • Preparation of HO—[—(CH[0118] 2CH2O—)nCO2]m(—CH2CH2O)n—H(Nave=22; m=2 from benzyl-O—(CH2CH2O)n—H(nave=22) and Bt-O2C—O—(CH2CH2O)n—CO2Bt(nave=22)
  • Azeotropically dried benzyl-PEG[0119] 1 KDa-OH (40.6 g, 40.6 mmoles), Bt-O2C—O-PEG1 KDa-O—CO2-Bt (25 g, 20.3 mmoles) and dimethylaminopyridine (5 g, 81.2 mmoles) was mixed in 300 ml of acetonitrile. The reaction was stirred at 75-80° C. overnight. The solvent was removed by rotary evaporation and the product was precipitated using diethyl ether/isopropyl alcohol (500 ml, 50/50) in an ice bath. The product was collected by filtration and dried under vacuum. The dry product was placed in a 500 ml Parr bottle and dissolved in 100 ml of anhydrous 1,4-dioxane. 11.0 g of Pd/C (10% pd by wt.) was added and the bottle pressurized with 45 psi of hydrogen and shaken for 20.5 hours. The mixture was filtered to remove the Pd/C and the solvent removed by rotary evaporation. The crude solid was precipitated by adding 500 ml of isopropyl alcohol. The product was collected by filtration and dried under vacuum. The product was demonstrated to be greater than 98% pure with a polydispersity of 1.034 by GPC.
  • Preparation of NS—O[0120] 2C—O-PEC3 KDa-O—CO2—NS(NS=N-succinimidyl) from HO-PEC3 KDa-OH
  • The dried HO-PEC[0121] 3 KDa-OH was dissolved in anhydrous CH3CN (150 ml) and stirred at room temperature under argon. Di-N-succinimidyl carbonate (2.6 g, 10 mmoles) was added and allowed to dissolve before pyridine (0.81 ml, 10 mmoles) was added. The reaction mixture was stirred overnight (15 hrs.) The CH3CN was removed under vacuum. The crude solid was dissolved in CH2Cl2 (100 ml) and washed once with buffer solution (100 ml). The aqueous layer was extracted with an additional 50 ml of CH2Cl2 and the combined organic layers were dried using Na2SO4. The solvent was removed under vacuum until a viscous residue remained. To this was added IPA (500 ml) to precipitate the product. The product was collected by filtration and dried under vacuum. The product was demonstrated by 1H nmr to have greater than 95% purity.
  • EXAMPLE 13
  • Hydrolysis Kinetics of a Single Carbonate Linkage in a PEC Polymer [0122]
  • CH[0123] 3O—(CH2CH2O)n—CO2(CH2CH2O)n—OCH3(nave=113) (1 wt. % in buffer, pH 7.4) was thermostated at 37° C. and the hydrolysis rate of the carbonate linkage was measured by analysis of the product using GPC. The half-life for hydrolysis under these conditions was found to be 44 days.
  • The foregoing description is to be considered illustrative rather than descriptive of the invention. Therefore, it should be understood that the specific embodiments described herein are illustrative of how the invention may be practiced and that modifications and other embodiments are intended to be included within the scope of the appended claims. [0124]

Claims (96)

What is claimed is:
1. A hydrolytically degradable polymer comprising two or more oligomers linked to each other by hydrolytically degradable carbonate linkages, wherein said oligomers comprise two or more alkylene oxide monomers.
2. The polymer of claim 1, wherein said oligomers are made of ethylene oxide monomers.
3. The polymer of claim 1 wherein said oligomers are made of monomers selected from the group consisting of ethylene oxide, propylene oxide, and butylene oxide.
4. The polymer of claim 1 further comprising at least one reactive terminal moiety.
5. The polymer of claim 4, wherein said reactive terminal moiety is selected from the group consisting of N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, tresyl, 1-imidazolylcarbonyl, vinylsulfone, acryloyl, iodoacetamide, N-succinimidylpropionate, N-succinimidylbutyrate, N-succinimidylacetate, and o-pyridyldithiyl.
6. The polymer of claim 1, wherein each of said oligomers is composed of from about 10 to about 50 monomers.
7. A polymer having the formula of:
X—O—[(—CH2CH2—O—)n—CO2]m—(CH2CH2O)n—Y
where n is an integer of from about 2 to about 2,000, m is an integer of from about 2 to about 200, and where X and Y each independently is H, alkyl, alkenyl, aryl, or a reactive moiety, and X and Y can be same or different.
8. The polymer of claim 7, wherein X and Y are independently selected from the group consisting of H, alkyl, alkenyl, aryl, acryloyl, methacryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.
9. The polymer of claim 7, wherein X and Y are 1-benzotriazolyloxy carbonyl.
10. The polymer of claim 7, wherein X and Y are acryloyl or methacryloyl.
11. The polymer of claim 7, wherein X and Y are N-succinimidyl carbonyl.
12. The polymer of claim 7, wherein n is an integer of from about 5 to about 500.
13. The polymer of claim 7, wherein n is an integer of from about 10 to about 50.
14. The polymer of claim 7, wherein m is an integer of from about 10 to about 50.
15. A method for preparing a hydrolytically degradable polymer comprising:
providing an oligomer having a hydroxyl group at one terminus and, at another terminus, a functional group of —O—CO2-Z which is capable of reacting with a hydroxyl group to form a carbonate linkage, wherein Z is a reactive leaving group, and wherein said oligomer comprises two or more alkylene oxide monomers; and
polymerizing said oligomer at conditions sufficient to form said hydrolytically degradable polymer, wherein the polymer has two or more said oligomers linked to each other by hydrolytically degradable carbonate linkages.
16. The method of claim 15, further comprising activating said hydrolytically degradable polymer to form at least one reactive terminal moiety on said polymer.
17. The method of claim 15, further comprising purifying said hydrolytically degradable polymer.
18. The method of claim 15, wherein said oligomer consists of ethylene oxide monomers.
19. The method of claim 15, wherein said polymer has the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 2 to about 2000, m is an integer of from about 2 to about 100, and wherein said oligomer has the formula of:
HO—(—CH2CH2—O—)n—O—CO2-Z
wherein n as defined above, Z is a reactive leaving group.
20. The method of claim 19, wherein Z is N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl.
21. The method of claim 19, wherein the polymerizing step is conducted in a solvent in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
22. The method of claim 21, wherein said solvent is selected from the group consisting of acetonitrile, dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes, chloroform, and methylene chloride.
23. The method of claim 21, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
24. The method of claim 19, wherein the polymerizing step is conducted in melt in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
25. The method of claim 24, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
26. The method of claim 19, wherein n is an integer of from about 10 to about 50.
27. The method of claim 19, wherein m is an integer of from about 5 to about 100.
28. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, comprising:
polymerizing an ethylene oxide oligomer having a formula of
HO—(—CH2CH2—O—)n—O—CO2-1-benzotriazolyl
in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
29. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, comprising:
polymerizing an ethylene oxide oligomer having a formula of
HO—(—CH2CH2—O—)n—O—CO2-N-succinimidyl
in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
30. A method for preparing a hydrolytically degradable polymer comprising:
providing a first oligomer having a first functional group of —O—CO2—W at one terminus and, at another terminus, a second functional group of —O—CO2-Z, wherein each of said functional groups is capable of reacting with a hydroxyl group to form a carbonate linkage, and wherein Z and W are reactive leaving groups and can be same or different;
providing a second oligomer having two hydroxyl terminal groups;
providing a polymerization reaction mixture comprising said first and second oligomers; and
polymerizing said first and second oligomers at conditions sufficient to form said hydrolytically degradable polymer, wherein said polymer has two or more of said oligomers linked to each other by a hydrolytically degradable carbonate linkage, and wherein each of said oligomers comprises two or more alkylene oxide monomers.
31. The method of claim 30, further comprising activating said hydrolytically degradable polymer to form at least one reactive terminal moiety on said polymer.
32. The method of claim 30, further comprising purifying said hydrolytically degradable polymer.
33. The method of claim 30, wherein said first and second oligomers consist of ethylene oxide monomers.
34. The method of claim 30, wherein the first oligomer has a functional group of —O—CO2-Z at two termini, and the step of providing the first oligomer comprises:
providing a precursor of the first oligomer, which has two terminal hydroxyl groups;
providing an activating molecule having the formula of Z-O—CO2-Z; and
reacting said precursor with said activating molecule to form said first oligomer.
35. The method of claim 30, wherein said polymer has the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
said first oligomer has the formula of
HO—(—CH2CH2—O—)n—OH
said second oligomer has the formula of
W—O2C—O—(—CH2CH2—O—)n—O—CO2-Z
where n is an integer of from about 2 to about 2000, m is an integer of from about 2 to about 100, W and Z are reactive leaving groups and can be same or different.
36. The method of claim 35, wherein W and Z are N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl.
37. The method of claim 35, wherein the polymerizing step is conducted in a solvent in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
38. The method of claim 37, wherein said solvent is selected from the group consisting of acetonitrile, dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes, chloroform, and methylene chloride.
39. The method of claim 37, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
40. The method of claim 35, wherein wherein the polymerizing step is conducted in melt in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
41. The method of claim 40, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
42. The method of claim 35, wherein n is from about 10 to about 50.
43. The method of claim 35, wherein m is from about 5 to about 100.
44. The method of claim 35, wherein W and Z are same, and wherein said step of providing said second oligomer comprises:
providing an activating molecule having the formula of Z-O—CO2-Z;
providing a precursor of said second oligomer having two terminal hydroxyl groups; and
reacting Z-O—CO2-Z and said precursor to form said second oligomer.
45. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, comprising:
providing a first ethylene oxide oligomer having the formula of
HO—(—CH2CH2—O—)n—OH;
providing a second ethylene oxide oligomer having a formula of
1-benzotriazolyl-O2C—O—(—CH2CH2—O—)n—O—CO2-1-benzotriazolyl; and
co-polymerizing said first and second ethylene oxide oligomer in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
46. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, comprising:
providing a first ethylene oxide oligomer having the formula of
HO—(—CH2CH2—O—)n—OH;
providing a second ethylene oxide oligomer having a formula of
N-succinimidyl-O2C—O—(—CH2CH2—O—)n—O—CO2—N-succinimidyl; and
co-polymerizing said first and second ethylene oxide oligomer in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
47. A method for preparing a hydrolytically degradable polymer comprising:
providing an alkylene oxide oligomer having two hydroxyl terminal groups;
providing an activating molecule having the formula of Z-O—CO2-Z, wherein Z is a reactive leaving group; and
co-polymerizing said oligomer and said activating molecule at conditions sufficient to form said hydrolytically degradable polymer, wherein said polymer comprises two or more of said oligomer linked to each other by hydrolytically degradable carbonate linkages.
48. The method of claim 47, wherein said oligomer is an ethylene oxide oligomer.
49. The method claim 47, wherein said polymer has the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H,
said oligomer has the formula of
HO—(—CH2CH2—O—)n—OH,
where n is an integer of from about 2 to about 2000, m is an integer of from about 2 to about 200.
50. The method of claim 49, wherein Z is N-succinimidyl, 1-benzotriazolyl, or p-nitrophenyl.
51. The method of claim 49, wherein the co-polymerizing step is conducted in a solvent in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
52. The method of claim 51, wherein said solvent is selected from the group consisting of acetonitrile, dimethylformamide, dimethylsulfoxide, benzene, toluene, xylenes, chloroform, and methylene chloride.
53. The method of claim 51, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
54. The method of claim 49, wherein said polymerizing step is conducted in melt in the presence of an organic base, and at a temperature of from about 37° C. to about 100° C.
55. The method of claim 54, wherein said organic base is selected from the group consisting of triethylamine, pyridine, quinoline, and 4,4-dimethylaminopyridine.
56. The method of claim 49, wherein n is from about 10 to about 50.
57. The method of claim 49, wherein m is from about 5 to about 100.
58. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, comprising co-polymerizing disuccinimidylcarbonate and
HO—(—CH2CH2—O—)n—OH,
in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
59. A method for preparing a polymer having the formula of:
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
wherein n is an integer of from about 10 to about 50, m is an integer of from about 2 to about 100, comprising co-polymerizing bis(l-benzotriazolyl carbonate) and
HO—(—CH2CH2—O—)n—OH,
in the presence of dimethylaminopyridine and at a temperature of from about 45° C. to about 100° C., either in melt or in anhydrous acetonitrile as solvent, thereby forming said polymer.
60. A conjugate comprising a biologically active agent covalently linked to a hydrolytically degradable polymer, said polymer comprising two or more alkylene oxide oligomers linked to each other by hydrolytically degradable carbonate linkages.
61. The conjugate of claim 60, wherein said biologically active agent is a protein or peptide.
62. The conjugate of claim 60, wherein said biologically active agent is covalently linked to said hydrolytically degradable polymer by a hydrolytically degradable linkage.
63. The conjugate of claim 60, wherein said oligomers are ethylene oxide oligomers.
64. A conjugate comprising of a biologically active agent covalently linked to a hydrolytically degradable polymer having the formula of:
X—O—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—Y
where n is an integer of from about 2 to about 2000, m is an integer of from about 2 to about 100, X and Y each independently is H, alkyl, alkenyl, aryl, or a reactive moiety capable of reacting with an active moiety on said biologically active agent, X and Y can be same or different, and where at least one of X and Y is said reactive moiety.
65. The conjugate of claim 64, wherein X and Y are independently selected from the group consisting of H, alkyl, alkenyl, aryl, acryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.
66. The conjugate of claim 64, wherein at least one of X and Y is N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl.
67. The conjugate of claim 64, wherein n is an integer of from about 5 to about 500.
68. The conjugate of claim 64, wherein n is an integer of from about 10 to about 50.
69. The conjugate of claim 64, wherein m is an integer of from about 5 to about 100.
70. A method for preparing a conjugate having a biologically active agent covalently linked to a hydrolytically degradable polymer, said polymer comprising two or more alkylene oxide oligomers linked to each other by hydrolytically degradable carbonate linkages, said method comprising the steps of:
providing said hydrolytically degradable polymer;
activating said hydrolytically degradable polymer to form a reactive terminal moiety in said polymer;
providing a biologically active agent having an active moiety; and
reacting said reactive terminal moiety in said polymer with said active moiety of said biologically active agent, thereby forming a covalent linkage between said biologically active agent and said polymer.
71. The method of claim 70, wherein said reactive terminal moiety is selected from the group consisting of tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.
72. The method of claim 70, wherein said active moiety of said biologically active agent is an amine or thiol group.
73. The method of claim 70, wherein the said alkylene oxide oligomers are made of ethylene oxide monomers.
74. The method of claim 70, wherein the polymer has the formula of
HO—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—H
where n is an integer of from about 5 to about 500, and m is an integer of from about 5 to about 100.
75. The method of claim 74, wherein n is an integer of from about 10 to about 50.
76. A method for delivering a biologically active agent into the body of a mammal, comprising administering the conjugate of claim 60 into said mammal.
77. A method for delivering a biologically active agent into the body of a mammal, comprising administering the conjugate of claim 64 into said mammal.
78. A hydrolytically degradable hydrogel comprising a backbone bonded to a crosslinking agent, wherein said crosslinking agent is a hydrolytically degradable polymer having at least two reactive terminal moieties, said polymer comprising two or more alkylene oxide oligomers linked to each other by hydrolytically degradable carb
79. The hydrolytically degradable hydrogel of claim 78, wherein the alkylene oxide oligomers are made of ethylene oxide monomers.
80. The hydrolytically degradable hydrogel of claim 78, wherein said at least two reactive terminal moieties a re selected from the group consisting of N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, tresyls, 1-imidazolylcarbonyl, vinylsulfone, acryloyl, vinyl, iodoacetamide, and o-pyridyldithiyl.
81. The hydrolytically degradable hydrogel of claim 78, wherein said backbone is a biocompatible molecule having at least two active groups available to react with said terminal reactive moieties.
82. The hydrolytically degradable hydrogel of claim 78, wherein said backbone is selected from the group consisting of proteins, polyamines, polyols, amino carbohydrates, polythiols, polycarboxylic acids, and poly(ethylene glycol) amines.
83. The hydrolytically degradable hydrogel of claim 78, wherein said backbone is chitosan.
84. The hydrolytically degradable hydrogel of claim 78, wherein said backbone and said crosslinking agent have the same chemical formula having two terminal vinyl groups or terminal acryloyl or methacryloyl groups.
85. The hydrolytically degradable hydrogel of claim 78, wherein said crosslinking agent is a hydrolytically degradable polymer having the formula of:
X—O—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—Y
where n is an integer of from about 2 to about 2000, m is an integer of from about 2 to about 100, and where X and Y each independently is a reactive moiety, and X and Y can be same or different.
86. The hydrolytically degradable hydrogel of claim 85, wherein X and Y are independently selected from the group consisting of acryloyl, tresyl, N-succinimidyloxycarbonyl, 1-benzotriazolyloxycarbonyl, p-nitrophenyloxycarbonyl, N-maleimidyl, aldehydes, acetals, 1-imidazolylcarbonyl, vinylsulfone, iodoacetamide, and o-pyridyldithiyl.
87. The hydrolytically degradable hydrogel of claim 85, wherein X and Y are 1-benzotriazolyl carbonyl.
88. The hydrolytically degradable hydrogel of claim 85, wherein the backbone has the same chemical formula as the crosslinking agent, and wherein X and Y are acrylate or methacrylate.
89. The hydrolytically degradable hydrogel of claim 85, wherein X and Y are N-succinimidyl carbonyl.
90. The hydrolytically degradable hydrogel of claim 85, wherein n is an integer of from about 5 to about 500.
91. The hydrolytically degradable hydrogel of claim 85, wherein n is an integer of from about 10 to about 50.
92. The hydrolytically degradable hydrogel of claim 85, wherein m is an integer of from about 5 to about 100.
93. A hydrolytically degradable hydrogel comprising chitosan bonded to a hydrolytically degradable polymer having the formula of:
NS—O2C—O—[(—CH2CH2—O—)n—CO2—]m—(CH2CH2O)n—CO2—NS
where n is an integer of from about 10 to about 50, m is an integer of from about 5 to about 100, and where NS is N-succinimidyl.
94. A delivery system for delivering a biologically active agent comprising the biologically active agent carried by a hydrolytically degradable hydrogel of claim 78.
95. The delivery system of claim 94, wherein said biologically active agent is covalently linked to the hydrogel.
96. A delivery system for delivering a biologically active agent comprising the biologically active agent carried by a hydrolytically degradable hydrogel of claim 85.
US10/076,018 1999-12-10 2002-02-14 Hydrolytically degradable polymers and hydrogels made therefrom Abandoned US20030023023A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/076,018 US20030023023A1 (en) 1999-12-10 2002-02-14 Hydrolytically degradable polymers and hydrogels made therefrom
US10/412,642 US7074878B1 (en) 1999-12-10 2003-04-10 Hydrolytically degradable polymers and hydrogels made therefrom
US11/377,973 US7259224B2 (en) 1999-12-10 2006-03-17 Hydrolytically degradable polymers and hydrogels made therefrom
US11/890,162 US7608678B2 (en) 1999-12-10 2007-08-03 Hydrolytically degradable polymers and hydrogels made therefrom
US12/559,162 US7772357B2 (en) 1999-12-10 2009-09-14 Hydrolytically degradable polymers and hydrogels made therefrom
US12/826,664 US7910685B2 (en) 1999-12-10 2010-06-29 Hydrolytically degradable polymers and hydrogels made therefrom
US13/027,218 US8119756B2 (en) 1999-12-10 2011-02-14 Hydrolytically degradable polymers and hydrogels made therefrom
US13/344,434 US8283434B2 (en) 1999-12-10 2012-01-05 Hydrolytically degradable polymers and hydrogels made therefrom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,312 US6348558B1 (en) 1999-12-10 1999-12-10 Hydrolytically degradable polymers and hydrogels made therefrom
US10/076,018 US20030023023A1 (en) 1999-12-10 2002-02-14 Hydrolytically degradable polymers and hydrogels made therefrom

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/459,312 Continuation US6348558B1 (en) 1999-12-10 1999-12-10 Hydrolytically degradable polymers and hydrogels made therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/412,642 Continuation US7074878B1 (en) 1999-12-10 2003-04-10 Hydrolytically degradable polymers and hydrogels made therefrom

Publications (1)

Publication Number Publication Date
US20030023023A1 true US20030023023A1 (en) 2003-01-30

Family

ID=23824266

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/459,312 Expired - Lifetime US6348558B1 (en) 1999-12-10 1999-12-10 Hydrolytically degradable polymers and hydrogels made therefrom
US10/076,018 Abandoned US20030023023A1 (en) 1999-12-10 2002-02-14 Hydrolytically degradable polymers and hydrogels made therefrom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/459,312 Expired - Lifetime US6348558B1 (en) 1999-12-10 1999-12-10 Hydrolytically degradable polymers and hydrogels made therefrom

Country Status (1)

Country Link
US (2) US6348558B1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170404A1 (en) * 2004-02-02 2005-08-04 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060019347A1 (en) * 2004-07-21 2006-01-26 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20060183198A1 (en) * 2004-12-22 2006-08-17 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US20080107680A1 (en) * 2004-12-22 2008-05-08 Ambrx, Inc. Modified Human Growth Hormone
US20090123971A1 (en) * 2004-12-22 2009-05-14 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
US20090324478A1 (en) * 2004-04-13 2009-12-31 Hinman Norman D Method for Making Silicon-Containing Products
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US20110217343A1 (en) * 2002-02-15 2011-09-08 Nektar Therapeutics Hydrolytically degradable alkylene oxide based polymers
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8283434B2 (en) 1999-12-10 2012-10-09 Nektar Therapeutics Hydrolytically degradable polymers and hydrogels made therefrom
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9133276B2 (en) 2010-09-17 2015-09-15 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
US9265723B2 (en) 2009-07-31 2016-02-23 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11342163B2 (en) 2016-02-12 2022-05-24 Lam Research Corporation Variable depth edge ring for etch uniformity control
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
EP1061954B1 (en) * 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US7347850B2 (en) * 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak Biocompatible crosslinked polymers
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6376604B2 (en) * 1999-12-22 2002-04-23 Shearwater Corporation Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
EP1423093A4 (en) * 2001-04-23 2005-11-30 Wisconsin Alumni Res Found Bifunctional-modified hydrogels
EP1419191B1 (en) * 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US6765069B2 (en) * 2001-09-28 2004-07-20 Biosurface Engineering Technologies, Inc. Plasma cross-linked hydrophilic coating
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
DK2311432T3 (en) * 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
MXPA04012496A (en) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms.
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
US7803777B2 (en) * 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20080146782A1 (en) * 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT2644206T (en) * 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CA2536873C (en) * 2003-08-29 2019-09-10 Dyax Corp. Poly-pegylated protease inhibitors
CN107090025A (en) 2003-11-05 2017-08-25 达纳-法伯癌症研究所股份有限公司 Stable alpha helical peptides and application thereof
KR20060120141A (en) * 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
NZ547554A (en) * 2003-12-03 2009-09-25 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005070138A2 (en) * 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
JP2008505853A (en) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド Non-natural ribonuclease complex as a cytotoxic agent
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
ES2395732T3 (en) 2004-08-02 2013-02-14 Samyang Corporation Biodegradable multi-block polymer composition susceptible to sol-gel transition
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8834901B2 (en) * 2004-10-14 2014-09-16 Trustees Of Tufts College Electrochemically degradable polymers
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
JP2006296511A (en) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc External preparation, method for applying external preparation, iontophoresis device, and transdermal patch
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP1898955A2 (en) * 2005-06-17 2008-03-19 Nektar Therapeutics AL, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
EP1926768B1 (en) 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
DK1922350T3 (en) 2005-07-29 2015-03-09 Nektar Therapeutics Methods for preparing polymerreagenser
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2009509675A (en) * 2005-09-30 2009-03-12 Tti・エルビュー株式会社 Transdermal drug delivery systems, devices, and methods using novel pharmaceutical vehicles
JP2009509677A (en) * 2005-09-30 2009-03-12 Tti・エルビュー株式会社 Iontophoretic delivery of vesicle encapsulated active substances
US20070078375A1 (en) * 2005-09-30 2007-04-05 Transcutaneous Technologies Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
KR20080066712A (en) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 Functionalized microneedles transdermal drug delivery systems, devices, and methods
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2007079193A2 (en) * 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
KR101513732B1 (en) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 Segmented degradable polymers and conjugates made therefrom
JP2009541333A (en) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
EP2049151A4 (en) * 2006-07-17 2010-03-24 Quintessence Biosciences Inc Methods and compositions for the treatment of cancer
WO2008011633A2 (en) * 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
EP2123259A1 (en) * 2007-01-16 2009-11-25 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (en) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ Stitched polypeptide
PL2144923T3 (en) * 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
RU2482841C2 (en) * 2007-05-18 2013-05-27 ТиТиАй Эллебо, Инк. Devices for transdermal delivery, providing improved release of active substance through biological surface
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
JP2010187707A (en) * 2007-06-12 2010-09-02 Hokkaido Univ Liposome preparation for iontophoresis comprising insulin encapsulated therein
ES2551123T3 (en) * 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
JP5647899B2 (en) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーratiopharm GmbH Glycoconjugation of polypeptides using oligosaccharyltransferase
WO2009102952A2 (en) 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
US8745133B2 (en) * 2008-03-28 2014-06-03 Yahoo! Inc. System and method for optimizing the storage of data
CA2736495A1 (en) * 2008-09-10 2010-03-18 Gregory A. Smith Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2344199A1 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
EP2334336A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
WO2010033221A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
EP2334333A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of v681-like peptides
US9206223B2 (en) * 2008-09-22 2015-12-08 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
CN102227443B (en) 2008-10-01 2014-05-14 昆特森斯生物科学公司 Therapeutic ribonucleases
GB0820865D0 (en) * 2008-11-14 2008-12-24 Membrane Extraction Tech Ltd Degradable supports for tide synthesis
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102458451B (en) 2009-06-09 2016-10-05 普罗朗制药有限责任公司 Hemoglobin compositions
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN106913902A (en) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 Polysaccharide based aquagel
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
EP2521568B1 (en) 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
CN103119055A (en) 2010-05-17 2013-05-22 塞比克斯公司 Pegylated C-Peptide
DK2603600T3 (en) 2010-08-13 2019-03-04 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US10822374B2 (en) 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
MX358886B (en) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Peptidomimetic macrocyles.
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (en) 2012-02-15 2022-05-03 艾瑞朗医疗公司 Peptidomimetic macrocycles
CA2925035C (en) 2012-09-26 2021-05-25 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
BR112015009470A2 (en) 2012-11-01 2019-12-17 Aileron Therapeutics Inc disubstituted amino acids and their methods of preparation and use
BR112015022872A2 (en) 2013-03-13 2017-11-07 Harvard College stapled and stitched polypeptides, their use, their method of preparation, their composition and amino acid
AU2014228777B2 (en) 2013-03-15 2018-11-08 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
IL295414A (en) 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treatment of diabetic macular edema
JP7059003B2 (en) 2014-05-14 2022-04-25 トラスティーズ・オブ・ダートマス・カレッジ Deimmunized lysostaphin and how to use
CN114805527A (en) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 RAS inhibitory peptides and uses thereof
CN112245565A (en) 2014-09-24 2021-01-22 艾瑞朗医疗公司 Peptidomimetic macrocycles and uses thereof
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
JP2018511594A (en) 2015-03-18 2018-04-26 マサチューセッツ インスティテュート オブ テクノロジー Selective MCL-1-binding peptide
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6918712B2 (en) 2015-07-02 2021-08-11 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Stabilized antimicrobial peptide
US11078246B2 (en) 2015-08-28 2021-08-03 Dana-Farber Cancer Institute, Inc. Peptides binding to Bfl-1
JP2018528217A (en) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Peptidomimetic macrocycles as modulators of MCL-1
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN109069578A (en) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 For treating the intracellular targeted antimicrobial peptides of the stitching of infection
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
US11466064B2 (en) 2016-08-26 2022-10-11 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
JP7305614B2 (en) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Stabilized antimicrobial peptides for the treatment of antibiotic-resistant bacterial infections
AU2018383633A1 (en) 2017-12-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
US20200354413A1 (en) 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
CN115068659A (en) 2017-12-20 2022-09-20 史赛克欧洲运营有限责任公司 Biomedical foams
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US20200408746A1 (en) 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
US11286299B2 (en) 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
EP3962933A1 (en) 2019-04-18 2022-03-09 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
EP4077361A1 (en) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
AU2020408070A1 (en) 2019-12-20 2022-06-09 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
WO2021178714A2 (en) 2020-03-04 2021-09-10 Dana-Farber Cancer Institute, Inc. ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
AU2021258205A1 (en) 2020-04-22 2022-10-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof
US20230192789A1 (en) 2020-04-27 2023-06-22 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
CN116801908A (en) 2020-10-14 2023-09-22 丹娜法伯癌症研究院 Chimeric conjugates for degrading viral and host proteins and methods of use
US20240002450A1 (en) 2020-11-05 2024-01-04 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
WO2023039474A1 (en) 2021-09-08 2023-03-16 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
IT1248061B (en) 1991-06-14 1995-01-05 Mediolanum Farmaceutici Spa POLYCARBONATES AND THEIR USE FOR THE PREPARATION OF BIOERODIBLE MATRICES
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
FR2777895A1 (en) 1998-04-28 1999-10-29 Debio Rech Pharma Sa Non crosslinked block polymer useful as support for active agents e.g. antigens and vaccines

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283434B2 (en) 1999-12-10 2012-10-09 Nektar Therapeutics Hydrolytically degradable polymers and hydrogels made therefrom
US9040060B2 (en) 2002-02-15 2015-05-26 Nektar Therapeutics Hydrolytically degradable alkylene oxide based polymers
US20110217343A1 (en) * 2002-02-15 2011-09-08 Nektar Therapeutics Hydrolytically degradable alkylene oxide based polymers
US20050170404A1 (en) * 2004-02-02 2005-08-04 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20080097083A1 (en) * 2004-02-02 2008-04-24 Ambrx, Inc. Modified Human Four Helical Bundle Polypeptides and Their Uses
US20050220762A1 (en) * 2004-02-02 2005-10-06 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8119603B2 (en) 2004-02-02 2012-02-21 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US20080103293A1 (en) * 2004-02-02 2008-05-01 Ambrx, Inc. Modified Human Growth Hormone Polypeptides and Their Uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP2327724A2 (en) 2004-02-02 2011-06-01 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20080146781A1 (en) * 2004-02-02 2008-06-19 Ambrx, Inc. Modified Human Four Helical Bundle Polypeptides and Their Uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20080207877A1 (en) * 2004-02-02 2008-08-28 Ambrx, Inc. Modified Human Four Helical Bundle Polypeptides and Their Uses
US20090324478A1 (en) * 2004-04-13 2009-12-31 Hinman Norman D Method for Making Silicon-Containing Products
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US20060153860A1 (en) * 2004-06-18 2006-07-13 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20080085277A1 (en) * 2004-06-18 2008-04-10 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20080081038A1 (en) * 2004-06-18 2008-04-03 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20080050374A1 (en) * 2004-06-18 2008-02-28 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20100048871A1 (en) * 2004-07-21 2010-02-25 Ambrx, Inc. Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
US20060019347A1 (en) * 2004-07-21 2006-01-26 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US20060183198A1 (en) * 2004-12-22 2006-08-17 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2284191A2 (en) 2004-12-22 2011-02-16 Ambrx, Inc. Process for the preparation of hGH
US20090123971A1 (en) * 2004-12-22 2009-05-14 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US20080199909A1 (en) * 2004-12-22 2008-08-21 Ambrx, Inc. Methods for Expression and Purification of Recombinant Human Growth Hormone
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US20100174054A1 (en) * 2004-12-22 2010-07-08 Ambrx, Inc. Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US20080107680A1 (en) * 2004-12-22 2008-05-08 Ambrx, Inc. Modified Human Growth Hormone
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US20080125574A1 (en) * 2006-09-08 2008-05-29 Ambrx, Inc. Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3225248A1 (en) 2008-07-23 2017-10-04 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9457066B2 (en) 2009-07-31 2016-10-04 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US9265723B2 (en) 2009-07-31 2016-02-23 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
US11559482B2 (en) 2009-07-31 2023-01-24 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
EP4302783A2 (en) 2010-08-17 2024-01-10 Ambrx, Inc. Modified relaxin polypeptides and their uses
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9133276B2 (en) 2010-09-17 2015-09-15 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
EP3584255A1 (en) 2012-08-31 2019-12-25 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US11342163B2 (en) 2016-02-12 2022-05-24 Lam Research Corporation Variable depth edge ring for etch uniformity control
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
US6348558B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
US6348558B1 (en) Hydrolytically degradable polymers and hydrogels made therefrom
US8119756B2 (en) Hydrolytically degradable polymers and hydrogels made therefrom
US9040060B2 (en) Hydrolytically degradable alkylene oxide based polymers
US6461603B2 (en) Water-soluble polymer conjugates of artelinic acid
CA2394716C (en) Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
CA2431977C (en) Synthesis of high molecular weight non-peptidic polymer derivatives
US5548035A (en) Biodegradable copolymer as drug delivery matrix comprising polyethyleneoxide and aliphatic polyester blocks
AU2002246705A1 (en) Synthesis of high molecular weight non-peptidic polymer derivatives
EP1976896B1 (en) High efficiency method of preparing polyalkylene oxide carboxylic acids
AU2281001A (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
JP2002531217A (en) Biocompatible crosslinked polymer
US9006349B2 (en) Temperature-sensitive polyethylene glycol / polyester block copolymer in which bioactive functional group is introduced into side chain thereof
US6300458B1 (en) High molecular weight polymers and copolymers of BHMDO for biomedical application
EP1905793A1 (en) Method for producing biodegradable polyoxyalkylene

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA

Free format text: CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564

Effective date: 20021202

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: NEKTAR THERAPEUTICS, CALIFORNIA

Free format text: MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date: 20090731

Owner name: NEKTAR THERAPEUTICS,CALIFORNIA

Free format text: MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date: 20090731